WO2018230686A1 - Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess - Google Patents
Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess Download PDFInfo
- Publication number
- WO2018230686A1 WO2018230686A1 PCT/JP2018/022846 JP2018022846W WO2018230686A1 WO 2018230686 A1 WO2018230686 A1 WO 2018230686A1 JP 2018022846 W JP2018022846 W JP 2018022846W WO 2018230686 A1 WO2018230686 A1 WO 2018230686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- genus
- bacteria belonging
- belonging
- bacteria
- therapeutic agent
- Prior art date
Links
- 201000003453 lung abscess Diseases 0.000 title claims abstract description 89
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 206010035669 Pneumonia aspiration Diseases 0.000 title claims abstract description 48
- 201000009807 aspiration pneumonia Diseases 0.000 title claims abstract description 48
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 43
- 208000033809 Suppuration Diseases 0.000 title abstract description 4
- 210000004072 lung Anatomy 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- ZFIOCUITTUUVPV-MEDUHNTESA-N 7-[(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C([C@@H]1[C@H](F)CN(C1)C1=C(C2=C(C(C(C(O)=O)=CN2CCF)=O)C=C1F)OC)NC1CC1 ZFIOCUITTUUVPV-MEDUHNTESA-N 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 154
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 42
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 22
- 241000122116 Parvimonas Species 0.000 claims description 21
- 241000605909 Fusobacterium Species 0.000 claims description 17
- DTYLXDLAOLOTKT-UHFFFAOYSA-N 1,4-dihydroquinoline-3-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)=CNC2=C1 DTYLXDLAOLOTKT-UHFFFAOYSA-N 0.000 claims description 16
- 241000191992 Peptostreptococcus Species 0.000 claims description 16
- 241000606125 Bacteroides Species 0.000 claims description 13
- 241000605861 Prevotella Species 0.000 claims description 12
- 241000194017 Streptococcus Species 0.000 claims description 8
- 241000186046 Actinomyces Species 0.000 claims description 7
- 241000605894 Porphyromonas Species 0.000 claims description 7
- 241000131405 Tissierella Species 0.000 claims description 4
- 241000911872 Streptococcus anginosus group Species 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 8
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 10
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000002547 new drug Substances 0.000 description 7
- 238000011976 chest X-ray Methods 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 241001617393 Finegoldia Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000007012 clinical effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229960002625 pazufloxacin Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003504 Aspiration Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241001135221 Prevotella intermedia Species 0.000 description 3
- 241001135223 Prevotella melaninogenica Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 229960003702 moxifloxacin Drugs 0.000 description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- PKLMRMLZKXZQHS-UHFFFAOYSA-N 1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FCCN1C=C(C(C2=CC=CC(=C12)OC)=O)C(=O)O PKLMRMLZKXZQHS-UHFFFAOYSA-N 0.000 description 2
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 2
- 241000186066 Actinomyces odontolyticus Species 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 241000192016 Finegoldia magna Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000605952 Fusobacterium necrophorum Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001453171 Leptotrichia Species 0.000 description 2
- 241000123728 Leptotrichia buccalis Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001464887 Parvimonas micra Species 0.000 description 2
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001135213 Porphyromonas endodontalis Species 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 241001135217 Prevotella buccae Species 0.000 description 2
- 241001135261 Prevotella oralis Species 0.000 description 2
- 241001291896 Streptococcus constellatus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000167878 Tissierella creatinini Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 229960003177 sitafloxacin Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VAYISIYCRRTUOV-UHFFFAOYSA-N 1-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1=CC=C2N(OC)C=C(C(O)=O)C(=O)C2=C1 VAYISIYCRRTUOV-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241000933025 Actinomyces europaeus Species 0.000 description 1
- 241000511656 Actinomyces georgiae Species 0.000 description 1
- 241000511654 Actinomyces gerencseriae Species 0.000 description 1
- 241000544634 Actinomyces graevenitzii Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 241001464988 Actinomyces neuii Species 0.000 description 1
- 241000163019 Actinomyces radicidentis Species 0.000 description 1
- 241000900280 Actinomyces radingae Species 0.000 description 1
- 241001147825 Actinomyces sp. Species 0.000 description 1
- 241000900275 Actinomyces turicensis Species 0.000 description 1
- 241001478947 Actinomyces urogenitalis Species 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241001195773 Bacteroides massiliensis Species 0.000 description 1
- 241001122266 Bacteroides nordii Species 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241001122267 Bacteroides salyersiae Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- OBAPBKQMRWCKOX-UHFFFAOYSA-N Cl.OC(=O)C1=CNc2ccccc2C1 Chemical compound Cl.OC(=O)C1=CNc2ccccc2C1 OBAPBKQMRWCKOX-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000605956 Fusobacterium mortiferum Species 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 241000258937 Hemiptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 241000029613 Leptotrichia goodfellowii Species 0.000 description 1
- 241000029588 Leptotrichia hofstadii Species 0.000 description 1
- 241000495747 Leptotrichia hongkongensis Species 0.000 description 1
- 241000029603 Leptotrichia shahii Species 0.000 description 1
- 241001558986 Leptotrichia trevisanii Species 0.000 description 1
- 241000029590 Leptotrichia wadei Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000351207 Peptoniphilus Species 0.000 description 1
- 241000530062 Peptoniphilus harei Species 0.000 description 1
- 241000530065 Peptoniphilus ivorii Species 0.000 description 1
- 241001464881 Peptoniphilus lacrimalis Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 241000684246 Peptostreptococcus stomatis Species 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 241001135239 Porphyromonas levii Species 0.000 description 1
- 241000770209 Porphyromonas uenonis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000987248 Prevotella bergensis Species 0.000 description 1
- 241001135215 Prevotella bivia Species 0.000 description 1
- 241001135206 Prevotella buccalis Species 0.000 description 1
- 241001135209 Prevotella denticola Species 0.000 description 1
- 241001135219 Prevotella disiens Species 0.000 description 1
- 241000605951 Prevotella loescheii Species 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 241001135262 Prevotella oris Species 0.000 description 1
- 241000864367 Prevotella pallens Species 0.000 description 1
- 241000665168 Prevotella pleuritidis Species 0.000 description 1
- 241000530934 Prevotella timonensis Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001327082 Tissierella creatinophila Species 0.000 description 1
- 241000167944 Tissierella praeacuta Species 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241001533207 Veillonella atypica Species 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 208000022506 anaerobic bacteria infectious disease Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960001430 garenoxacin Drugs 0.000 description 1
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- -1 quinolone compound Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess.
- Patent Document 1 discloses a quinolone carboxylic acid derivative represented by the general formula (1) (Patent Document 1).
- R 1 is an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms, and 3 to 6 carbon atoms which may be substituted with one or more halogen atoms.
- R 2 is a hydrogen atom; alkyl group, a pharmaceutically acceptable cation,
- R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group or an alkyl group having 1 to 3 carbon atoms,
- R 4 represents a hydrogen atom or a halogen atom,
- Patent Document 1 discloses 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6 as one of the quinolonecarboxylic acid derivatives described above. -Fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is disclosed. The hydrochloride is disclosed in Patent Document 2.
- aspiration pneumonia is one of the respiratory infections.
- Aspiration pneumonia is a disease that accounts for the majority of pneumonia in the elderly and is a serious disease that is refractory, relapsed, and has a high fatality rate (Non-patent Document 1).
- Anaerobic bacteria, Staphylococcus aureus, and enterobacteria are mentioned as the causative bacteria of aspiration pneumonia (Non-patent Document 1), but a method for effectively treating aspiration pneumonia has been established so far. Absent.
- the quinolone preparations currently on the market include levofloxacin, ciprofloxacin, pazufloxacin, moxifloxacin, sitafloxacin and garenoxacin.
- Non-patent Document 2 For aspiration pneumonia, which is a high-severity disease, most of the initial treatment uses injectable preparations.
- levofloxacin, ciprofloxacin and Pazufloxacin has insufficient antibacterial activity against anaerobic bacteria and is not recommended for use in patients suspected of aspiration pneumonia (Non-patent Document 2).
- sitafloxacin, moxifloxacin and galenoxacin may be effective against anaerobic bacterial infections (Non-Patent Documents 3 to 5), but high for aspiration pneumonia There are no reports of articles with evidence, and no effective treatment has been established to date.
- Non-patent Document 6 As in the case of aspiration pneumonia, a lung abscess is an example of a respiratory infection mainly caused by anaerobic bacteria (Non-patent Document 6). Although there are reports that therapeutic effects are recognized for moxifloxacin and pazufloxacin (Non-Patent Documents 3 to 4 and Non-Patent Document 7), it has not been established as an effective treatment method to date.
- An object of the present invention is to provide a novel therapeutic agent for respiratory infections.
- the inventors of the present invention have made extensive studies on the above-mentioned problems, and found that 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1 Found that-(2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is extremely effective as a treatment for aspiration pneumonia, pulmonary abscess or lung abscess The present invention has been reached.
- the gist of the present invention is as follows. [1] 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess containing 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- a therapeutic agent for pulmonary abscess or lung abscess comprising 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- the causative bacteria of the aspiration pneumonia, pulmonary abscess or lung abscess are bacteria belonging to the genus Prevotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyllus, genus Finegordia
- the therapeutic agent according to [1] which is one type or two or more types of bacteria selected from the group consisting of bacteria belonging to genus and bacteria belonging to the genus Fusobacterium.
- the bacteria causing the aspiration pneumonia are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and Fusobacterium genus
- the therapeutic agent according to [2] which is one or more bacteria selected from the group consisting of bacteria belonging to.
- the pathogenic bacteria of the pulmonary abscess or lung abscess are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and
- the bacteria causing aspiration pneumonia, pulmonary abscess or lung abscess belong to a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prevotella, a bacterium belonging to the genus Porphyromonas, a bacterium belonging to the genus Fusobacterium, or the genus Leptotricia
- the therapeutic agent according to [1] which is two or more types of bacteria.
- the pathogenic bacterium of the aspiration pneumonia is selected from the group consisting of a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prebotella, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella and the genus Actinomyces,
- the therapeutic agent according to [2] which is two or more kinds of bacteria.
- the pulmonary abscess or pulmonary abscess causing bacteria are bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Prebotella, bacteria belonging to the genus Porphyromonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, peptostreptococcus [3] which is one or more bacteria selected from the group consisting of a bacterium belonging to the genus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, and a Streptococcus anginasus group, The therapeutic agent described.
- a therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess comprising administering to a patient methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof can be provided.
- the therapeutic agent of this embodiment relates to a therapeutic agent for respiratory diseases, but particularly relates to a therapeutic agent for respiratory infections. More specifically, the therapeutic agent of this embodiment is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- Aspiration comprising administering (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to a patient, including a human.
- the present invention relates to a therapeutic agent for pneumonia, pulmonary abscess or lung abscess.
- a respiratory infection refers to an infection that occurs at any site in the respiratory tract.
- the respiratory organ is a general term for organs related to respiration, and refers to organs from the nasal vestibule to the alveoli via the nasal cavity, pharynx, larynx, trachea, bronchi, and bronchioles.
- aspiration pneumonia is a respiratory condition including swelling and infection of the lungs and airways, and is considered to be caused by inhaling harmful substances.
- Patients with aspiration pneumonia may have symptoms such as coughing and dyspnea.
- a patient with aspiration pneumonia means a person who satisfies the following criteria.
- ⁇ A clear infiltrative shadow that appeared acutely on chest X-rays or CT images is observed.
- ⁇ A clear aspiration has been confirmed, repetition of bugs has been confirmed, dysfunction in the swallowing function evaluation test has been confirmed, or a complication or history of a disease with the possibility of swallowing dysfunction
- Symptoms and inflammation that are characteristic of aspiration pneumonia include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
- pulmonary abscess is a necrotizing pulmonary infection which is also called a lung abscess and is thought to be caused by inhalation of bacteria in the mouth and throat into the lungs.
- Patients with pulmonary abscess may have symptoms such as fatigue, loss of appetite, night sweats, fever, weight loss, and cough with sputum.
- a patient with pulmonary abscess means a person who satisfies the following criteria. ⁇ On chest X-rays or CT images, massive shadows or shadows with cavities inside (nodular shadows, tumor shadows) are observed.
- pulmonary abscess and lung abscess include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
- Non-patent Document 2 an injection of a quinolone compound such as levofloxacin, ciprofloxacin or pazufloxacin is considered not suitable as a therapeutic agent for aspiration pneumonia.
- Non-patent Document 2 the applicant is not able to use 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8- Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof are effective against anaerobic pathogens and effective in the treatment of aspiration pneumonia I found out.
- bacteria belonging to the genus Bacteroides (genus Bacteroides), bacteria belonging to the genus Prevotella (genus Prevotella), genus Porphyromonas (genus Porphyromonas) ), Bacteria belonging to the genus Fusobacterium (genus Fusobacterium), bacteria belonging to the genus Leptotrichia (genus Leptotrichia), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), genus Bayonella (Veillonella), bacteria belonging to the genus Tissierella (genus Tissierella), bacteria belonging to the genus Peptonitphilus (genus Peptonitphilus), bacteria belonging to the genus Finegoldia (genus Finegoldia)
- bacteria that cause aspiration pneumonia include bacteria belonging to the genus Prevotella (genus Prevotella), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), and the genus Peptonifilus (genus Peptonitphilus)
- bacteria belonging to the genus Finegoldia bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Streptococcus, and the like.
- the causative bacteria of aspiration pneumonia are the bacteria belonging to the genus Bacteroides, the bacteria belonging to the genus Prevotella, the bacteria belonging to the genus Parvimonas, the bacteria belonging to the genus Bayonella, or the genus Actinomyces. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8
- the high therapeutic effect of -methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is exerted.
- bacteria that cause pulmonary abscess or lung abscess include bacteria belonging to the genus Prevotella (genus Prevotella), bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas (genus Parvimonas), ), Bacteria belonging to the genus Finegoldia (genus Finegoldia), bacteria belonging to the genus Fusobacterium (genus Fusobacterium), bacteria belonging to the genus Bacteroides (genus Bacteroides), bacteria belonging to the genus Streptococcus, and the like.
- the causative bacteria of pulmonary abscess or lung abscess are bacteria belonging to the genus Prevoterra, bacteria belonging to the genus Porphynomonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) in the case of a bacterium belonging to the genus Peptostreptococcus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, or the Streptococcus anginasus group ) Methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4
- bacteria belonging to the genus Prebotella include, for example, P. denticola, P. loescheii, P. melaninogenica, P. intermedia, P. nigrescens, P. pallens, P. buccae, P. oris, P. buccalis, P. oralis, P. Bivia, P. disiens, P. pleuritidis, P. bergensis, P. timonensis, or P. nanceiencis genus.
- bacteria belonging to the genus Parvimonas include P. micra. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is P. micra.
- Peptoniphilus asaccharolyticus examples include Peptoniphilus asaccharolyticus, Peptoniphilus ivorii, Peptoniphilus lacrimalis, or Peptoniphilus harei. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is Peptoniphilus asaccharolyticus.
- Examples of bacteria belonging to the genus Finegordia include Finegoldia magna. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is Finegoldia magna.
- Examples of the bacteria belonging to the genus Fusobacterium include F. necrophorum, F. nucleatum, F. mortiferum, and F. varium. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is F. nucleatum or F. necrophorum.
- B. fragilis is the causative agent of pulmonary abscess or lung abscess.
- bacteria belonging to the genus Porphyromonas include P. gingivalis, P. endodontalis, P. asaccharolytica, P. levii, or P. uenonis. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the pulmonary abscess or pulmonary abscess pathogen is P. gingivalis or P. endodontalis.
- bacteria belonging to the genus Leptotricia examples include L. buccalis, L. hofstadii, L. hongkongensis, L. shahii, L. goodfellowii, L. trevisanii, or L. wadei. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is L. buccalis.
- the bacteria belonging to the genus Bayonella examples include V. parvula, V. atypica, and V. montpelliensis.
- bacteria belonging to the genus Tissierella include T. creatinini, T. creatinophila, or T. praeacuta. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is T. creatinini.
- bacteria belonging to the Streptococcus anginosas group examples include S. intermedius or S. constellatus. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo
- the pathogenic bacteria of pulmonary abscess or lung abscess are S. intermedius or S. constellatus.
- Actinomyces As a bacterium belonging to the genus Actinomyces, for example, A. europaeus, A. georgiae, A. gerencseriae, A. graevenitzii, A. israelii, A. meyeri, A. naeslundii, A. neuii, A. odontolyticus, A. radicidentis , A. radingae, A. turicensis, A. urogenitalis, A. viscocus, or Actinomyces sp..
- the causative bacterium is a concept including a bacterium that has acquired drug resistance.
- Drug resistance means a phenomenon in which an organism has resistance to a drug and the drug does not work or becomes difficult to work.
- Examples of drug resistance include penicillin resistance, cephalosporin resistance, carbapenem resistance, aminoglycoside resistance, macrolide resistance, lincomycin resistance, trimethoprim-sulfamethoxazole resistance, tetracycline resistance, metronidazole resistance, glycopeptide resistance, oxazolidinone resistance, Examples include daptomycin resistance or quinolone resistance. *
- additives contained with -methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid include, for example, excipients, lubricants, binders, disintegrants, stable Agents, flavoring agents, and diluents. These additives are not particularly limited as long as they can be used for the production of pharmaceutical preparations. For example, they are described in the Pharmaceutical Additives Dictionary “Japan Pharmaceutical Additives Association, Yakuji Nippo (2007)”. Can be used as appropriate.
- the therapeutic agent of the present embodiment can be administered to a subject such as a human by applying conventionally well-known pharmacological forms and administration routes.
- a subject such as a human by applying conventionally well-known pharmacological forms and administration routes.
- powders, tablets, capsules, fine granules, granules , Syrups, injections, ophthalmic solutions, aqueous nasal drops, aqueous ear drops, inhalation solutions and the like can be administered orally or parenterally.
- the therapeutic agent of this embodiment can be produced by mixing the active ingredient with a physiologically acceptable carrier, excipient, binder, diluent, etc., for example, in the dosage form as exemplified above.
- the maximum daily dose is preferably 300 mg or less, 250 mg or less, 200 mg or less, or 175 mg or less. 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo
- the daily dose of 1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is, for example, from 10 mg to 300 mg, more preferably from 20 mg to 250 mg, still more preferably Is from 50 mg to 200 mg, even more preferably from 100 mg to 200 mg, even more preferably from 125 mg to 175 mg, particularly preferably 150 mg.
- the dose per day is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2
- a pharmaceutically acceptable salt of (fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is used, the value converted into a free form is used.
- the daily dose may be administered once or divided into 2 to 3 times, but once daily administration is preferred. If the effect is insufficient, a dose twice the daily dose may be used.
- the loading administration means an administration design for reaching a target blood concentration at an early stage by increasing the daily dosage or increasing the number of daily administrations at the initial stage of administration.
- the initial period of administration means the first day to the third day of the start of administration, preferably the first day to the second day of the start of administration, and more preferably the first day of the start of administration.
- as an increase in daily dose preferably twice the daily dose is used.
- the daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 300 mg on the administration start date in terms of free form, After the first day, it is 150 mg.
- 1,4-dihydroquinoline-3-carboxylic acid hydrochloride is preferably 300 mg on the administration start date and 150 mg on and after the second administration date.
- the dose is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) It means a value obtained by converting -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride into a free form.
- a pharmaceutically acceptable salt can be used.
- the pharmaceutically acceptable salt include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, maleic acid, fumaric acid, succinic acid, malic acid, malonic acid, methanesulfonic acid, toluene.
- Salts with organic acids such as sulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, acetic acid, trifluoroacetic acid, tartaric acid, or sodium, potassium, magnesium, calcium, aluminum, cesium, chromium, cobalt, copper, iron, zinc, Examples thereof include salts with metals such as platinum and silver. Of these, hydrochloride is particularly preferable. *
- the “free form” means 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidine-1 which is neither a salt, a co-crystal nor a hydrate.
- -Yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, the molecular formula is C 21 H 24 F 3 N 3 O 4 is a compound having a molecular weight of 439.44.
- the therapeutic agent of this embodiment is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof may be constituted alone as an active ingredient.
- the therapeutic agent of this embodiment is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoro Ethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, other compounds acting as active ingredients and / or pharmaceutically acceptable You may make it comprise as a pharmaceutical composition containing an additive.
- the pharmaceutical composition may contain one or more compounds as other compounds that act as active ingredients and / or pharmaceutically acceptable additives.
- the pharmaceutical composition is, for example, 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof and one or more other compounds and additives that act as active ingredients To be prepared.
- security with respect to aspiration pneumonia, pulmonary abscess, or a lung abscess can be provided.
- an appropriate composition described in the present specification even when a small dose is used, a sufficient therapeutic effect can be obtained while reducing side effects and reducing the appearance frequency of resistant bacteria.
- 150 mg of 150 mg injection is 7-[(3S, 4S) -3- ⁇ (cyclopropylamino) methyl ⁇ -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2- It shows the weight when fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride is converted to free form.
- Test Examples 1 and 2 are as follows: Clinical evaluation of new antibacterial agents in respiratory infections (2nd edition), JCIA Journal. 2012; 60 (1): 30-45. 9) Based on the judgment criteria, the following criteria were set and judged. The primary endpoint was the effective rate at the end of administration or discontinuation of study drug A.
- the term “at the end of administration” means the evaluation date on the day after the administration of the investigational drug A is completed.
- the time of discontinuation means the evaluation date implemented within 3 days from the last administration date or the discontinuation judgment date of the investigational drug A.
- “when administration is completed or stopped” is expressed as treatment end (EOT, End of Treatment).
- CRP is an abbreviation for C-reactive protein, and is one of the acute phase reactants produced in a short time in response to various inflammations. Bacterial infections such as pneumonia increase in a few hours and decrease rapidly as the inflammation subsides. This is a useful index for observation of therapeutic effects.
- EOT Early efficacy evaluation and end of treatment
- CRP or chest X-ray findings do not change or worsen, and clinical symptoms and body temperature do not change or improve, it is determined that there is no early treatment effect.
- the investigator made an appropriate decision, such as switching to antibiotics. Samples for microbiological evaluation were collected before starting appropriate alternative antimicrobial treatment.
- the discontinuation date is the start date of administration (day 0) or the second day of administration (day 1)
- the determination of early drug efficacy is unnecessary.
- the test result at the time of discontinuation was used.
- the clinical effects at the end of administration or at the time of discontinuation were determined according to Table 1 in three stages: “effective”, “invalid”, and “undecidable”.
- Tables 2 and 3 show the results of early drug efficacy evaluation and treatment completion in Test Examples 1 and 2.
- Tables 4 and 5 show the microbiological effects of Test Examples 1 and 2 according to the causative bacteria.
Abstract
[Problem] The present invention pertains to a safer and more efficient therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess, the agent containing as an active ingredient 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
Description
本発明は、誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤に関する。
The present invention relates to a therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess.
ノルフロキサシンの開発以来、ニューキノロンと呼ばれるキノロンカルボン酸系抗菌剤の開発が全世界で行われ、現在では、多くのニューキノロン系抗菌剤が感染症治療薬として汎用されている。
Since the development of norfloxacin, quinolone carboxylic acid antibacterial agents called new quinolones have been developed all over the world. At present, many new quinolone antibacterial agents are widely used as infectious agents.
一方、出願人により、一般式（１）で表されるキノロンカルボン酸誘導体が開示されている（特許文献１）。
On the other hand, the applicant discloses a quinolone carboxylic acid derivative represented by the general formula (1) (Patent Document 1).
式（１）中、Ｒ１はハロゲン原子で１または２以上置換されていてもよい炭素数１から６のアルキル基、ハロゲン原子で１または２以上置換されていてもよい炭素数３から６のシクロアルキル基、またはハロゲン原子およびアミノ基から選択される同一または異なる置換基で１または２以上置換されていてもよいアリール基もしくはヘテロアリール基を、Ｒ２は水素原子、炭素数１から３のアルキル基、医薬的に許容される陽イオンを、Ｒ３は水素原子、ハロゲン原子、水酸基、アミノ基または炭素数１から３のアルキル基を、Ｒ４は水素原子またはハロゲン原子を、Ｒ５はフッ素原子を、Ｒ６は水素原子またはフッ素原子を、Ａは窒素原子または＝Ｃ－Ｘ（Ｘは水素原子、ハロゲン原子、アミノ基、シアノ基、ハロゲン原子で１または２以上置換されていてもよい炭素数１から３のアルキル基または炭素数１から３のアルコキシ基を示す）を示す。
In formula (1), R 1 is an alkyl group having 1 to 6 carbon atoms which may be substituted with one or more halogen atoms, and 3 to 6 carbon atoms which may be substituted with one or more halogen atoms. A cycloalkyl group, or an aryl group or heteroaryl group which may be substituted with one or more substituents selected from the same or different substituents selected from a halogen atom and an amino group; R 2 is a hydrogen atom; alkyl group, a pharmaceutically acceptable cation, R 3 is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group or an alkyl group having 1 to 3 carbon atoms, R 4 represents a hydrogen atom or a halogen atom, R 5 is fluorine atom, a R 6 is a hydrogen atom or a fluorine atom, a is a nitrogen atom or = C-X (X is a hydrogen atom, a halogen atom, an amino group, a cyano group, one or a halogen atom It shows the above substituted from good 1 -C shows a 3 alkyl or alkoxy group having 1 to 3 carbon atoms).
また、特許文献１には、上述のキノロンカルボン酸誘導体の1つとして、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸が開示されている。また、その塩酸塩が特許文献２に開示されている。
Patent Document 1 discloses 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6 as one of the quinolonecarboxylic acid derivatives described above. -Fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is disclosed. The hydrochloride is disclosed in Patent Document 2.
また、呼吸器感染症の一つに、誤嚥性肺炎が挙げられる。誤嚥性肺炎は高齢者の肺炎の大部分を占める疾患であり難治性かつ再発性で致死率も高い重篤な疾患である（非特許文献１）。誤嚥性肺炎の起因菌として、嫌気性菌、黄色ブドウ球菌、腸内細菌が挙げられるが（非特許文献１）、現在までに誤嚥性肺炎を有効に治療するような方法は確立されていない。現在上市されているキノロン製剤には、レボフロキサシン、シプロフロキサシン、パズフロキサシン、モキシフロキサシン、シタフロキサシン及びガレノキサシン等がある。重症度の高い疾患である誤嚥性肺炎に対しては、初期治療では多くは注射用製剤が使用されるが、上述したキノロン製剤のうち、注射用製剤が存在するレボフロキサシン、シプロフロキサシン及びパズフロキサシンは嫌気性菌に対する抗菌力が不十分であり、誤嚥性肺炎を疑う患者への使用は推奨されていない（非特許文献２）。経口剤では、シタフロキサシン、モキシフロキサシン及びガレノキサシンについては、嫌気性菌感染症に対して効果を発揮する可能性があるものの（非特許文献３乃至５）、誤嚥性肺炎を対象とした高いエビデンスを持つ論文の報告はなく、現在までに有効な治療方法として確立されていない。
Also, aspiration pneumonia is one of the respiratory infections. Aspiration pneumonia is a disease that accounts for the majority of pneumonia in the elderly and is a serious disease that is refractory, relapsed, and has a high fatality rate (Non-patent Document 1). Anaerobic bacteria, Staphylococcus aureus, and enterobacteria are mentioned as the causative bacteria of aspiration pneumonia (Non-patent Document 1), but a method for effectively treating aspiration pneumonia has been established so far. Absent. The quinolone preparations currently on the market include levofloxacin, ciprofloxacin, pazufloxacin, moxifloxacin, sitafloxacin and garenoxacin. For aspiration pneumonia, which is a high-severity disease, most of the initial treatment uses injectable preparations. Among the quinolone preparations mentioned above, levofloxacin, ciprofloxacin and Pazufloxacin has insufficient antibacterial activity against anaerobic bacteria and is not recommended for use in patients suspected of aspiration pneumonia (Non-patent Document 2). In oral preparations, sitafloxacin, moxifloxacin and galenoxacin may be effective against anaerobic bacterial infections (Non-Patent Documents 3 to 5), but high for aspiration pneumonia There are no reports of articles with evidence, and no effective treatment has been established to date.
誤嚥性肺炎と同様に主に嫌気性菌を起因菌とする呼吸器感染症の例として肺膿瘍が挙げられる（非特許文献６）。モキシフロキサシンやパズフロキサシンについて治療効果が認められている報告もあるものの（非特許文献３乃至４及び非特許文献７）、現在までに有効な治療方法として確立されていない。
As in the case of aspiration pneumonia, a lung abscess is an example of a respiratory infection mainly caused by anaerobic bacteria (Non-patent Document 6). Although there are reports that therapeutic effects are recognized for moxifloxacin and pazufloxacin (Non-Patent Documents 3 to 4 and Non-Patent Document 7), it has not been established as an effective treatment method to date.
本発明は新規な呼吸器感染症治療剤を提供することを目的とする。
An object of the present invention is to provide a novel therapeutic agent for respiratory infections.
本発明者は、有効性及び安全性の高い呼吸器感染症治療剤について研究を行った。本発明者らは、上記の課題について鋭意検討を行い、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸が誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤として極めて有効であることを見出し、本発明に到達した。
The inventor conducted research on a therapeutic agent for respiratory infection that is highly effective and safe. The inventors of the present invention have made extensive studies on the above-mentioned problems, and found that 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1 Found that-(2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is extremely effective as a treatment for aspiration pneumonia, pulmonary abscess or lung abscess The present invention has been reached.
本発明の要旨は以下の通りである。
〔１〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤。
〔２〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎の治療剤。
〔３〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する肺化膿症又は肺膿瘍の治療剤。
〔４〕前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔１〕に記載の治療剤。
〔５〕前記誤嚥性肺炎の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔２〕に記載の治療剤。
〔６〕前記肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔３〕に記載の治療剤。
〔７〕前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、ストレプトコッカス・アンギノーサスグループ、及びアクチノマイセス属に属する菌からなる群から選ばれる１種または２種以上の菌である、〔１〕に記載の治療剤。
〔８〕前記誤嚥性肺炎の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌及びアクチノマイセス属からなる群から選ばれる１種または２種以上の菌である、〔２〕に記載の治療剤。
〔９〕前記肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、及びストレプトコッカス・アンギノーサスグループからなる群から選ばれる１種または２種以上の菌である、〔３〕に記載の治療剤。
〔１０〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔１〕に記載の治療剤。
〔１１〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔２〕に記載の治療剤。
〔１２〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔３〕に記載の治療剤。 The gist of the present invention is as follows.
[1] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess containing 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[2] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for aspiration pneumonia containing 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[3] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for pulmonary abscess or lung abscess comprising 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[4] The causative bacteria of the aspiration pneumonia, pulmonary abscess or lung abscess are bacteria belonging to the genus Prevotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyllus, genus Finegordia [1] The therapeutic agent according to [1], which is one type or two or more types of bacteria selected from the group consisting of bacteria belonging to genus and bacteria belonging to the genus Fusobacterium.
[5] The bacteria causing the aspiration pneumonia are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and Fusobacterium genus The therapeutic agent according to [2], which is one or more bacteria selected from the group consisting of bacteria belonging to.
[6] The pathogenic bacteria of the pulmonary abscess or lung abscess are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and The therapeutic agent according to [3], which is one or more bacteria selected from the group consisting of bacteria belonging to the genus Fusobacterium.
[7] The bacteria causing aspiration pneumonia, pulmonary abscess or lung abscess belong to a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prevotella, a bacterium belonging to the genus Porphyromonas, a bacterium belonging to the genus Fusobacterium, or the genus Leptotricia One species selected from the group consisting of a bacterium, a bacterium belonging to the genus Peptostreptococcus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tiescherella, a Streptococcus anginasus group, and a bacterium belonging to the genus Actinomyces Alternatively, the therapeutic agent according to [1], which is two or more types of bacteria.
[8] The pathogenic bacterium of the aspiration pneumonia is selected from the group consisting of a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prebotella, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella and the genus Actinomyces, The therapeutic agent according to [2], which is two or more kinds of bacteria.
[9] The pulmonary abscess or pulmonary abscess causing bacteria are bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Prebotella, bacteria belonging to the genus Porphyromonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, peptostreptococcus [3] which is one or more bacteria selected from the group consisting of a bacterium belonging to the genus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, and a Streptococcus anginasus group, The therapeutic agent described.
[10] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [1], wherein the administration start date is 300 mg, and 150 mg is administered on and after the second day of administration.
[11] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [2], wherein the administration start date is 300 mg, and the dose is 150 mg after the second day of administration.
[12] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [3], wherein the administration start date is 300 mg, and the dose is 150 mg after the second administration day.
〔１〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤。
〔２〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎の治療剤。
〔３〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する肺化膿症又は肺膿瘍の治療剤。
〔４〕前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔１〕に記載の治療剤。
〔５〕前記誤嚥性肺炎の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔２〕に記載の治療剤。
〔６〕前記肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、〔３〕に記載の治療剤。
〔７〕前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、ストレプトコッカス・アンギノーサスグループ、及びアクチノマイセス属に属する菌からなる群から選ばれる１種または２種以上の菌である、〔１〕に記載の治療剤。
〔８〕前記誤嚥性肺炎の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌及びアクチノマイセス属からなる群から選ばれる１種または２種以上の菌である、〔２〕に記載の治療剤。
〔９〕前記肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、及びストレプトコッカス・アンギノーサスグループからなる群から選ばれる１種または２種以上の菌である、〔３〕に記載の治療剤。
〔１０〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔１〕に記載の治療剤。
〔１１〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔２〕に記載の治療剤。
〔１２〕７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、〔３〕に記載の治療剤。 The gist of the present invention is as follows.
[1] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess containing 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[2] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for aspiration pneumonia containing 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[3] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- A therapeutic agent for pulmonary abscess or lung abscess comprising 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
[4] The causative bacteria of the aspiration pneumonia, pulmonary abscess or lung abscess are bacteria belonging to the genus Prevotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyllus, genus Finegordia [1] The therapeutic agent according to [1], which is one type or two or more types of bacteria selected from the group consisting of bacteria belonging to genus and bacteria belonging to the genus Fusobacterium.
[5] The bacteria causing the aspiration pneumonia are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and Fusobacterium genus The therapeutic agent according to [2], which is one or more bacteria selected from the group consisting of bacteria belonging to.
[6] The pathogenic bacteria of the pulmonary abscess or lung abscess are bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia, and The therapeutic agent according to [3], which is one or more bacteria selected from the group consisting of bacteria belonging to the genus Fusobacterium.
[7] The bacteria causing aspiration pneumonia, pulmonary abscess or lung abscess belong to a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prevotella, a bacterium belonging to the genus Porphyromonas, a bacterium belonging to the genus Fusobacterium, or the genus Leptotricia One species selected from the group consisting of a bacterium, a bacterium belonging to the genus Peptostreptococcus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tiescherella, a Streptococcus anginasus group, and a bacterium belonging to the genus Actinomyces Alternatively, the therapeutic agent according to [1], which is two or more types of bacteria.
[8] The pathogenic bacterium of the aspiration pneumonia is selected from the group consisting of a bacterium belonging to the genus Bacteroides, a bacterium belonging to the genus Prebotella, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella and the genus Actinomyces, The therapeutic agent according to [2], which is two or more kinds of bacteria.
[9] The pulmonary abscess or pulmonary abscess causing bacteria are bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Prebotella, bacteria belonging to the genus Porphyromonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, peptostreptococcus [3] which is one or more bacteria selected from the group consisting of a bacterium belonging to the genus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, and a Streptococcus anginasus group, The therapeutic agent described.
[10] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [1], wherein the administration start date is 300 mg, and 150 mg is administered on and after the second day of administration.
[11] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [2], wherein the administration start date is 300 mg, and the dose is 150 mg after the second day of administration.
[12] 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, The therapeutic agent according to [3], wherein the administration start date is 300 mg, and the dose is 150 mg after the second administration day.
本発明によれば、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を患者に投与することを含む、誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤を提供することができる。
According to the present invention, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8 A therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess comprising administering to a patient methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof Can be provided.
以下、本発明の実施形態の１つについて詳細に説明する。
本実施形態の治療剤は、呼吸器疾患の治療剤に関するが、特に呼吸器感染症の治療剤に関する。より具体的には、本実施形態の治療剤は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を、ヒトを含む患者に投与することを含む、誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤に関する。 Hereinafter, one embodiment of the present invention will be described in detail.
The therapeutic agent of this embodiment relates to a therapeutic agent for respiratory diseases, but particularly relates to a therapeutic agent for respiratory infections. More specifically, the therapeutic agent of this embodiment is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- Aspiration comprising administering (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to a patient, including a human. The present invention relates to a therapeutic agent for pneumonia, pulmonary abscess or lung abscess.
本実施形態の治療剤は、呼吸器疾患の治療剤に関するが、特に呼吸器感染症の治療剤に関する。より具体的には、本実施形態の治療剤は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を、ヒトを含む患者に投与することを含む、誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤に関する。 Hereinafter, one embodiment of the present invention will be described in detail.
The therapeutic agent of this embodiment relates to a therapeutic agent for respiratory diseases, but particularly relates to a therapeutic agent for respiratory infections. More specifically, the therapeutic agent of this embodiment is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- Aspiration comprising administering (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof to a patient, including a human. The present invention relates to a therapeutic agent for pneumonia, pulmonary abscess or lung abscess.
呼吸器感染症とは呼吸器におけるいずれかの部位において起こる感染症をいう。また、呼吸器とは、呼吸に関する器官の総称であり、鼻前庭から、鼻腔、咽頭、喉頭、気管、気管支、細気管支を経た肺胞までの器官をいう。
本明細書における、「誤嚥性肺炎」とは、肺や大気道の腫れや感染を含む呼吸状態であり、有害物質を吸い込むことで引き起こされると考えられている。誤嚥性肺炎に罹患した患者には、咳や呼吸困難といった症状が出ることがある。
本明細書において、誤嚥性肺炎の患者とは、下記の基準を満たす者を意味する。
・胸部Ｘ線またはCT画像上に急性に出現した明らかな浸潤影を認める。
・明らかな誤嚥が確認されている、むせの反復が確認されている、嚥下機能評価試験での機能障害が確認されている、または、嚥下機能障害の可能性をもつ疾患の合併もしくは既往歴を有する。
・誤嚥性肺炎に特徴的な症状、炎症所見を示す。
なお、誤嚥性肺炎に特徴的な症状、炎症所見とは、咳嗽、膿性痰、湿性ラ音、呼吸困難、発熱、CRP陽性、白血球増加、低酸素血症等である。 A respiratory infection refers to an infection that occurs at any site in the respiratory tract. The respiratory organ is a general term for organs related to respiration, and refers to organs from the nasal vestibule to the alveoli via the nasal cavity, pharynx, larynx, trachea, bronchi, and bronchioles.
As used herein, “aspiration pneumonia” is a respiratory condition including swelling and infection of the lungs and airways, and is considered to be caused by inhaling harmful substances. Patients with aspiration pneumonia may have symptoms such as coughing and dyspnea.
In this specification, a patient with aspiration pneumonia means a person who satisfies the following criteria.
・ A clear infiltrative shadow that appeared acutely on chest X-rays or CT images is observed.
・ A clear aspiration has been confirmed, repetition of bugs has been confirmed, dysfunction in the swallowing function evaluation test has been confirmed, or a complication or history of a disease with the possibility of swallowing dysfunction Have
-Symptoms and inflammation that are characteristic of aspiration pneumonia.
Symptoms and inflammation that are characteristic of aspiration pneumonia include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
本明細書における、「誤嚥性肺炎」とは、肺や大気道の腫れや感染を含む呼吸状態であり、有害物質を吸い込むことで引き起こされると考えられている。誤嚥性肺炎に罹患した患者には、咳や呼吸困難といった症状が出ることがある。
本明細書において、誤嚥性肺炎の患者とは、下記の基準を満たす者を意味する。
・胸部Ｘ線またはCT画像上に急性に出現した明らかな浸潤影を認める。
・明らかな誤嚥が確認されている、むせの反復が確認されている、嚥下機能評価試験での機能障害が確認されている、または、嚥下機能障害の可能性をもつ疾患の合併もしくは既往歴を有する。
・誤嚥性肺炎に特徴的な症状、炎症所見を示す。
なお、誤嚥性肺炎に特徴的な症状、炎症所見とは、咳嗽、膿性痰、湿性ラ音、呼吸困難、発熱、CRP陽性、白血球増加、低酸素血症等である。 A respiratory infection refers to an infection that occurs at any site in the respiratory tract. The respiratory organ is a general term for organs related to respiration, and refers to organs from the nasal vestibule to the alveoli via the nasal cavity, pharynx, larynx, trachea, bronchi, and bronchioles.
As used herein, “aspiration pneumonia” is a respiratory condition including swelling and infection of the lungs and airways, and is considered to be caused by inhaling harmful substances. Patients with aspiration pneumonia may have symptoms such as coughing and dyspnea.
In this specification, a patient with aspiration pneumonia means a person who satisfies the following criteria.
・ A clear infiltrative shadow that appeared acutely on chest X-rays or CT images is observed.
・ A clear aspiration has been confirmed, repetition of bugs has been confirmed, dysfunction in the swallowing function evaluation test has been confirmed, or a complication or history of a disease with the possibility of swallowing dysfunction Have
-Symptoms and inflammation that are characteristic of aspiration pneumonia.
Symptoms and inflammation that are characteristic of aspiration pneumonia include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
本明細書における、「肺化膿症」とは、肺膿瘍とも呼ばれ、口腔や喉の細菌が肺に吸い込まれることで引き起こされると考えられている、壊死性の肺感染症である。肺化膿症に罹患した患者には、疲労、食欲不振、寝汗、発熱、体重減少、痰を伴う咳といった症状が出ることがある。
本明細書において、肺化膿症の患者とは、下記の基準を満たす者を意味する。
・胸部Ｘ線またはＣＴ画像上、塊状影または内部に空洞を伴う陰影（結節影、腫瘤影）を認める。（膿の貯留による鏡面像の有無は問わない。）
・肺化膿症・肺膿瘍に特徴的な症状、炎症所見を示す。
なお、肺化膿症又は肺膿瘍に特徴的な症状、炎症所見とは、咳嗽、膿性痰、湿性ラ音、呼吸困難、発熱、CRP陽性、白血球増加、低酸素血症等である。 As used herein, “pulmonary abscess” is a necrotizing pulmonary infection which is also called a lung abscess and is thought to be caused by inhalation of bacteria in the mouth and throat into the lungs. Patients with pulmonary abscess may have symptoms such as fatigue, loss of appetite, night sweats, fever, weight loss, and cough with sputum.
In the present specification, a patient with pulmonary abscess means a person who satisfies the following criteria.
・ On chest X-rays or CT images, massive shadows or shadows with cavities inside (nodular shadows, tumor shadows) are observed. (It does not matter if there is a mirror image due to pus accumulation.)
-Symptoms and inflammation that are characteristic of pulmonary abscess and lung abscess.
Symptoms and inflammation that are characteristic of pulmonary abscess or lung abscess include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
本明細書において、肺化膿症の患者とは、下記の基準を満たす者を意味する。
・胸部Ｘ線またはＣＴ画像上、塊状影または内部に空洞を伴う陰影（結節影、腫瘤影）を認める。（膿の貯留による鏡面像の有無は問わない。）
・肺化膿症・肺膿瘍に特徴的な症状、炎症所見を示す。
なお、肺化膿症又は肺膿瘍に特徴的な症状、炎症所見とは、咳嗽、膿性痰、湿性ラ音、呼吸困難、発熱、CRP陽性、白血球増加、低酸素血症等である。 As used herein, “pulmonary abscess” is a necrotizing pulmonary infection which is also called a lung abscess and is thought to be caused by inhalation of bacteria in the mouth and throat into the lungs. Patients with pulmonary abscess may have symptoms such as fatigue, loss of appetite, night sweats, fever, weight loss, and cough with sputum.
In the present specification, a patient with pulmonary abscess means a person who satisfies the following criteria.
・ On chest X-rays or CT images, massive shadows or shadows with cavities inside (nodular shadows, tumor shadows) are observed. (It does not matter if there is a mirror image due to pus accumulation.)
-Symptoms and inflammation that are characteristic of pulmonary abscess and lung abscess.
Symptoms and inflammation that are characteristic of pulmonary abscess or lung abscess include cough, purulent sputum, moist rales, dyspnea, fever, CRP positive, leukocytosis, hypoxemia and the like.
嫌気性の病原菌に対して安全で有効な化合物を見つけることは、誤嚥性肺炎、肺化膿症又は肺膿瘍のような疾患を効果的に治療するために重要である。出願人は７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸および薬学的に許容されるその塩が、その他のキノロン化合物とは異なり、嫌気性の病原菌に対して効果的であることを見出した。例えば、レボフロキサシン、シプロフロキサシン又はパズフロキサシンなどのキノロン化合物の注射剤は、誤嚥性肺炎の治療剤として適切でないと考えられている（非特許文献２）。
しかし、出願人は７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸および薬学的に許容されるその塩が、嫌気性の病原菌に対し有効であり、誤嚥性肺炎の治療に対して効果的であることを見出した。 Finding safe and effective compounds against anaerobic pathogens is important to effectively treat diseases such as aspiration pneumonia, pulmonary abscess or lung abscess. Applicant is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- It has been found that 4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof are effective against anaerobic pathogens, unlike other quinolone compounds. For example, an injection of a quinolone compound such as levofloxacin, ciprofloxacin or pazufloxacin is considered not suitable as a therapeutic agent for aspiration pneumonia (Non-patent Document 2).
However, the applicant is not able to use 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8- Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof are effective against anaerobic pathogens and effective in the treatment of aspiration pneumonia I found out.
しかし、出願人は７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸および薬学的に許容されるその塩が、嫌気性の病原菌に対し有効であり、誤嚥性肺炎の治療に対して効果的であることを見出した。 Finding safe and effective compounds against anaerobic pathogens is important to effectively treat diseases such as aspiration pneumonia, pulmonary abscess or lung abscess. Applicant is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- It has been found that 4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof are effective against anaerobic pathogens, unlike other quinolone compounds. For example, an injection of a quinolone compound such as levofloxacin, ciprofloxacin or pazufloxacin is considered not suitable as a therapeutic agent for aspiration pneumonia (Non-patent Document 2).
However, the applicant is not able to use 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8- Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof are effective against anaerobic pathogens and effective in the treatment of aspiration pneumonia I found out.
なお、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩は、例えば特許文献１または２に記載の方法に従って製造することができる。
誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌となる偏性嫌気性菌として、バクテロイデス属（Bacteroides属）に属する菌、プレボテラ属（Prevotella属）に属する菌、ポルフィロモナス属（Porphyromonas属）に属する菌、フソバクテリウム属（Fusobacterium属）に属する菌、レプトトリキア属（Leptotrichia属）に属する菌、ペプトストレプトコッカス属（Peptostreptococcus属）に属する菌、パルビモナス属（Parvimonas属）に属する菌等、ベイヨネラ属（Veillonella属）に属する菌、ティシエレラ属（Tissierella属）に属する菌、ペプトニフィラス属（Peptoniｔphilus属）に属する菌、及びファインゴルディア属（Finegoldia属）に属する菌、通性嫌気性菌としてストレプトコッカス属に含まれるストレプトコッカス・アンギノーサスグループ（Streptococcus Anginosus group）、アクチノマイセス属（Actinomyces属）に属する菌等が挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸は、前述の嫌気性菌に対して高い抗菌力を発揮し、誤嚥性肺炎、肺化膿症又は肺膿瘍に対し、高い治療効果を示す。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4 -Oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof can be produced, for example, according to the method described in Patent Document 1 or 2.
As an obligate anaerobe that causes aspiration pneumonia, pulmonary abscess or lung abscess, bacteria belonging to the genus Bacteroides (genus Bacteroides), bacteria belonging to the genus Prevotella (genus Prevotella), genus Porphyromonas (genus Porphyromonas) ), Bacteria belonging to the genus Fusobacterium (genus Fusobacterium), bacteria belonging to the genus Leptotrichia (genus Leptotrichia), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), genus Bayonella (Veillonella), bacteria belonging to the genus Tissierella (genus Tissierella), bacteria belonging to the genus Peptonitphilus (genus Peptonitphilus), bacteria belonging to the genus Finegoldia (genus Finegoldia), Streptococcus as facultative anaerobes Included Streptococcus Anginosus group, Actino Bacteria such as belonging to Isis genus (Actinomyces genus) can be mentioned. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo 1,4-dihydroquinoline-3-carboxylic acid exhibits high antibacterial activity against the above-mentioned anaerobic bacteria and exhibits a high therapeutic effect against aspiration pneumonia, pulmonary abscess or lung abscess.
誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌となる偏性嫌気性菌として、バクテロイデス属（Bacteroides属）に属する菌、プレボテラ属（Prevotella属）に属する菌、ポルフィロモナス属（Porphyromonas属）に属する菌、フソバクテリウム属（Fusobacterium属）に属する菌、レプトトリキア属（Leptotrichia属）に属する菌、ペプトストレプトコッカス属（Peptostreptococcus属）に属する菌、パルビモナス属（Parvimonas属）に属する菌等、ベイヨネラ属（Veillonella属）に属する菌、ティシエレラ属（Tissierella属）に属する菌、ペプトニフィラス属（Peptoniｔphilus属）に属する菌、及びファインゴルディア属（Finegoldia属）に属する菌、通性嫌気性菌としてストレプトコッカス属に含まれるストレプトコッカス・アンギノーサスグループ（Streptococcus Anginosus group）、アクチノマイセス属（Actinomyces属）に属する菌等が挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸は、前述の嫌気性菌に対して高い抗菌力を発揮し、誤嚥性肺炎、肺化膿症又は肺膿瘍に対し、高い治療効果を示す。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4 -Oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof can be produced, for example, according to the method described in Patent Document 1 or 2.
As an obligate anaerobe that causes aspiration pneumonia, pulmonary abscess or lung abscess, bacteria belonging to the genus Bacteroides (genus Bacteroides), bacteria belonging to the genus Prevotella (genus Prevotella), genus Porphyromonas (genus Porphyromonas) ), Bacteria belonging to the genus Fusobacterium (genus Fusobacterium), bacteria belonging to the genus Leptotrichia (genus Leptotrichia), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), genus Bayonella (Veillonella), bacteria belonging to the genus Tissierella (genus Tissierella), bacteria belonging to the genus Peptonitphilus (genus Peptonitphilus), bacteria belonging to the genus Finegoldia (genus Finegoldia), Streptococcus as facultative anaerobes Included Streptococcus Anginosus group, Actino Bacteria such as belonging to Isis genus (Actinomyces genus) can be mentioned. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo 1,4-dihydroquinoline-3-carboxylic acid exhibits high antibacterial activity against the above-mentioned anaerobic bacteria and exhibits a high therapeutic effect against aspiration pneumonia, pulmonary abscess or lung abscess.
誤嚥性肺炎の起因菌として、例えば、プレボテラ属（Prevotella属 ）に属する菌、ペプトストレプトコッカス属（Peptostreptococcus属）に属する菌、パルビモナス属（Parvimonas属）に属する菌、ペプトニフィラス属（Peptoniｔphilus属）に属する菌、ファインゴルディア属（Finegoldia属）に属する菌、フソバクテリウム属（Fusobacterium属）に属する菌、バクテロイデス属（Bacteroides属）に属する菌、ストレプトコッカス属に含まれる菌等が挙げられる。
誤嚥性肺炎の治療に関しては、特に、誤嚥性肺炎の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、又はアクチノマイセス属に属する菌である場合、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の高い治療効果が発揮される。 Examples of bacteria that cause aspiration pneumonia include bacteria belonging to the genus Prevotella (genus Prevotella), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), and the genus Peptonifilus (genus Peptonitphilus) Examples include bacteria belonging to the genus Finegoldia, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Streptococcus, and the like.
Regarding the treatment of aspiration pneumonia, in particular, the causative bacteria of aspiration pneumonia are the bacteria belonging to the genus Bacteroides, the bacteria belonging to the genus Prevotella, the bacteria belonging to the genus Parvimonas, the bacteria belonging to the genus Bayonella, or the genus Actinomyces. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8 The high therapeutic effect of -methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is exerted.
誤嚥性肺炎の治療に関しては、特に、誤嚥性肺炎の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、又はアクチノマイセス属に属する菌である場合、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の高い治療効果が発揮される。 Examples of bacteria that cause aspiration pneumonia include bacteria belonging to the genus Prevotella (genus Prevotella), bacteria belonging to the genus Peptostreptococcus (genus Peptostreptococcus), bacteria belonging to the genus Parvimonas (genus Parvimonas), and the genus Peptonifilus (genus Peptonitphilus) Examples include bacteria belonging to the genus Finegoldia, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Streptococcus, and the like.
Regarding the treatment of aspiration pneumonia, in particular, the causative bacteria of aspiration pneumonia are the bacteria belonging to the genus Bacteroides, the bacteria belonging to the genus Prevotella, the bacteria belonging to the genus Parvimonas, the bacteria belonging to the genus Bayonella, or the genus Actinomyces. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8 The high therapeutic effect of -methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is exerted.
肺化膿症又は肺膿瘍の起因菌として、例えば、プレボテラ属（Prevotella属 ）に属する菌、ペプトストレプトコッカス属（Peptostreptococcus属）に属する菌、パルビモナス属（Parvimonas属）に属する菌、ペプトニフィラス属（Peptoniｔphilus属）に属する菌、ファインゴルディア属（Finegoldia属）に属する菌、フソバクテリウム属（Fusobacterium属）に属する菌、バクテロイデス属（Bacteroides属）に属する菌、ストレプトコッカス属に含まれる菌等が挙げられる。
Examples of bacteria that cause pulmonary abscess or lung abscess include bacteria belonging to the genus Prevotella (genus Prevotella), bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas (genus Parvimonas), ), Bacteria belonging to the genus Finegoldia (genus Finegoldia), bacteria belonging to the genus Fusobacterium (genus Fusobacterium), bacteria belonging to the genus Bacteroides (genus Bacteroides), bacteria belonging to the genus Streptococcus, and the like.
肺化膿症又は肺膿瘍の治療に関しては、特に、肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ポルフィノモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する、ベイヨネラ属に属する菌、ティシエレラ属に属する菌又はストレプトコッカス・アンギノーサスグループである場合、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の高い治療効果が発揮される。
Regarding the treatment of pulmonary abscess or lung abscess, in particular, the causative bacteria of pulmonary abscess or lung abscess are bacteria belonging to the genus Prevoterra, bacteria belonging to the genus Porphynomonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, 7-[(3S, 4S) -3-{(cyclopropylamino) in the case of a bacterium belonging to the genus Peptostreptococcus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, or the Streptococcus anginasus group ) Methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Is demonstrated.
プレボテラ属に属する菌として、例えば、P. denticola、P. loescheii、P. melaninogenica、P. intermedia、P. nigrescens、P. pallens、P. buccae、P. oris、P. buccalis、P. oralis、P. bivia、P. disiens、P. pleuritidis、P. bergensis、P. timonensis、又はP. nanceiencis属が挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎の起因菌が、P. melaninogenica、P. intermedia、又はP. buccaeである場合、肺化膿症又は肺膿瘍の起因菌が、P. melaninogenica、P. intermedia、又はP. oralisである場合が挙げられる。
ペプトストレプトコッカス属に属する菌として、例えば、P.anaerobius、又はP.stomatisが挙げられる。 Examples of bacteria belonging to the genus Prebotella include, for example, P. denticola, P. loescheii, P. melaninogenica, P. intermedia, P. nigrescens, P. pallens, P. buccae, P. oris, P. buccalis, P. oralis, P. Bivia, P. disiens, P. pleuritidis, P. bergensis, P. timonensis, or P. nanceiencis genus. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, when the causative organism of aspiration pneumonia is P. melaninogenica, P. intermedia, or P. buccae, pulmonary abscess And the pathogen causing pulmonary abscess may be P. melaninogenica, P. intermedia, or P. oralis.
Examples of bacteria belonging to the genus Peptostreptococcus include P. anaerobius or P. stomatis.
ペプトストレプトコッカス属に属する菌として、例えば、P.anaerobius、又はP.stomatisが挙げられる。 Examples of bacteria belonging to the genus Prebotella include, for example, P. denticola, P. loescheii, P. melaninogenica, P. intermedia, P. nigrescens, P. pallens, P. buccae, P. oris, P. buccalis, P. oralis, P. Bivia, P. disiens, P. pleuritidis, P. bergensis, P. timonensis, or P. nanceiencis genus. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, when the causative organism of aspiration pneumonia is P. melaninogenica, P. intermedia, or P. buccae, pulmonary abscess And the pathogen causing pulmonary abscess may be P. melaninogenica, P. intermedia, or P. oralis.
Examples of bacteria belonging to the genus Peptostreptococcus include P. anaerobius or P. stomatis.
パルビモナス属に属する菌として、例えば、P. micraが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、P. micraである場合が挙げられる。
ペプトニフィラス属に属する菌として、例えば、Peptoniphilus asaccharolyticus、Peptoniphilus ivorii、Peptoniphilus lacrimalis又はPeptoniphilus hareiが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、Peptoniphilus asaccharolyticusである場合が挙げられる。 Examples of bacteria belonging to the genus Parvimonas include P. micra. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is P. micra.
Examples of bacteria belonging to the genus Peptoniphilus include Peptoniphilus asaccharolyticus, Peptoniphilus ivorii, Peptoniphilus lacrimalis, or Peptoniphilus harei. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is Peptoniphilus asaccharolyticus.
ペプトニフィラス属に属する菌として、例えば、Peptoniphilus asaccharolyticus、Peptoniphilus ivorii、Peptoniphilus lacrimalis又はPeptoniphilus hareiが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、Peptoniphilus asaccharolyticusである場合が挙げられる。 Examples of bacteria belonging to the genus Parvimonas include P. micra. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is P. micra.
Examples of bacteria belonging to the genus Peptoniphilus include Peptoniphilus asaccharolyticus, Peptoniphilus ivorii, Peptoniphilus lacrimalis, or Peptoniphilus harei. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo More preferably, from the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is Peptoniphilus asaccharolyticus.
フィネゴルディア属に属する菌として、例えば、Finegoldia magnaが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、Finegoldia magnaである場合が挙げられる。
Examples of bacteria belonging to the genus Finegordia include Finegoldia magna. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of aspiration pneumonia, pulmonary abscess or lung abscess is Finegoldia magna.
フソバクテリウム属に属する菌として、例えば、F. necrophorum、F. nucleatum、F. mortiferum、又はF. variumが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌が、F. nucleatum、又はF. necrophorumである場合が挙げられる。
バクテロイデス属に属する菌として、例えば、B. fragilis、B. thetaiotaomicron、B. vulgatus、B. ovatus、B. uniformis、B. eggerthii、B. nordii、B. salyersae、又はB. massiliensisが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌がB. fragilisである場合が挙げられる。 Examples of the bacteria belonging to the genus Fusobacterium include F. necrophorum, F. nucleatum, F. mortiferum, and F. varium. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is F. nucleatum or F. necrophorum.
Examples of the bacteria belonging to the genus Bacteroides include B. fragilis, B. thetaiotaomicron, B. vulgatus, B. ovatus, B. uniformis, B. eggerthii, B. nordii, B. salyersae, or B. massiliensis. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, B. fragilis is the causative agent of pulmonary abscess or lung abscess.
バクテロイデス属に属する菌として、例えば、B. fragilis、B. thetaiotaomicron、B. vulgatus、B. ovatus、B. uniformis、B. eggerthii、B. nordii、B. salyersae、又はB. massiliensisが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌がB. fragilisである場合が挙げられる。 Examples of the bacteria belonging to the genus Fusobacterium include F. necrophorum, F. nucleatum, F. mortiferum, and F. varium. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is F. nucleatum or F. necrophorum.
Examples of the bacteria belonging to the genus Bacteroides include B. fragilis, B. thetaiotaomicron, B. vulgatus, B. ovatus, B. uniformis, B. eggerthii, B. nordii, B. salyersae, or B. massiliensis. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, B. fragilis is the causative agent of pulmonary abscess or lung abscess.
ポルフィロモナス属に属する菌として、例えば、P. gingivalis、P. endodontalis、P. asaccharolytica、P. levii、又はP. uenonisが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌が、P. gingivalis、又はP. endodontalisである場合が挙げられる。
Examples of bacteria belonging to the genus Porphyromonas include P. gingivalis, P. endodontalis, P. asaccharolytica, P. levii, or P. uenonis. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the pulmonary abscess or pulmonary abscess pathogen is P. gingivalis or P. endodontalis.
レプトトリキア属に属する菌として、例えば、L. buccalis、L. hofstadii、L. hongkongensis、L. shahii、L. goodfellowii、L. trevisanii、又はL. wadeiが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌が、L. buccalisである場合が挙げられる。
ベイヨネラ属に属する菌として、例えば、V. parvula、V. atypica、又はV. montpelliensisが挙げられる。 Examples of bacteria belonging to the genus Leptotricia include L. buccalis, L. hofstadii, L. hongkongensis, L. shahii, L. goodfellowii, L. trevisanii, or L. wadei. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is L. buccalis.
Examples of the bacteria belonging to the genus Bayonella include V. parvula, V. atypica, and V. montpelliensis.
ベイヨネラ属に属する菌として、例えば、V. parvula、V. atypica、又はV. montpelliensisが挙げられる。 Examples of bacteria belonging to the genus Leptotricia include L. buccalis, L. hofstadii, L. hongkongensis, L. shahii, L. goodfellowii, L. trevisanii, or L. wadei. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is L. buccalis.
Examples of the bacteria belonging to the genus Bayonella include V. parvula, V. atypica, and V. montpelliensis.
ティシエレラ属に属する菌として、例えば、T. creatinini、T. creatinophila、又はT. praeacutaが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌が、T. creatininiである場合が挙げられる。
Examples of bacteria belonging to the genus Tissierella include T. creatinini, T. creatinophila, or T. praeacuta. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of pulmonary abscess or lung abscess is T. creatinini.
ストレプトコッカス・アンギノーサスグループに属する菌として、例えば、S. intermedius、又はS. constellatusが挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、肺化膿症又は肺膿瘍の起因菌が、S. intermedius、又はS. constellatusである場合が挙げられる。
Examples of the bacteria belonging to the Streptococcus anginosas group include S. intermedius or S. constellatus. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the pathogenic bacteria of pulmonary abscess or lung abscess are S. intermedius or S. constellatus.
アクチノマイセス属に属する菌として、例えば、A. europaeus、A. georgiae、A. gerencseriae、A. graevenitzii、A. israelii、A. meyeri、A. naeslundii、A. neuii、A. odontolyticus、A. radicidentis、A. radingae、A. turicensis、A. urogenitalis、A. viscocus、又はActinomyces sp. が挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の治療効果という観点から、より好ましくは、誤嚥性肺炎の起因菌が、A. odontolyticusである場合が挙げられる。
As a bacterium belonging to the genus Actinomyces, for example, A. europaeus, A. georgiae, A. gerencseriae, A. graevenitzii, A. israelii, A. meyeri, A. naeslundii, A. neuii, A. odontolyticus, A. radicidentis , A. radingae, A. turicensis, A. urogenitalis, A. viscocus, or Actinomyces sp.. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo From the viewpoint of the therapeutic effect of 1,4-dihydroquinoline-3-carboxylic acid, more preferably, the cause of aspiration pneumonia is A. odontolyticus. *
本明細書における、起因菌とは、薬剤耐性を獲得した菌も含まれる概念である。薬剤耐性とは、生物が薬剤に対して抵抗性を持ち、薬剤が効かないまたは効きにくくなる現象を意味する。薬剤耐性の例として、ペニシリン耐性、セファロスポリン耐性、カルバペネム耐性、アミノグリコシド耐性、マクロライド耐性、リンコマイシン耐性、トリメトプリム－スルファメトキサゾール耐性、テトラサイクリン耐性、メトロニダゾール耐性、グリコペプチド耐性、オキサゾリジノン耐性、ダプトマイシン耐性又はキノロン耐性が挙げられる。
In the present specification, the causative bacterium is a concept including a bacterium that has acquired drug resistance. Drug resistance means a phenomenon in which an organism has resistance to a drug and the drug does not work or becomes difficult to work. Examples of drug resistance include penicillin resistance, cephalosporin resistance, carbapenem resistance, aminoglycoside resistance, macrolide resistance, lincomycin resistance, trimethoprim-sulfamethoxazole resistance, tetracycline resistance, metronidazole resistance, glycopeptide resistance, oxazolidinone resistance, Examples include daptomycin resistance or quinolone resistance. *
上述の医薬組成物において７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸とともに含有される薬学的に許容される添加剤としては、例えば、賦形剤、滑沢剤、結合剤、崩壊剤、安定剤、矯味矯臭剤、希釈剤が挙げられる。これらの添加剤としては、医薬品製剤の製造に使用可能なものであれば特に限定はなく、例えば、医薬品添加物事典「日本医薬品添加剤協会、薬事日報社（２００７年）」に記載されているものを適宜使用できる。
In the above pharmaceutical composition, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8 Pharmaceutically acceptable additives contained with -methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid include, for example, excipients, lubricants, binders, disintegrants, stable Agents, flavoring agents, and diluents. These additives are not particularly limited as long as they can be used for the production of pharmaceutical preparations. For example, they are described in the Pharmaceutical Additives Dictionary “Japan Pharmaceutical Additives Association, Yakuji Nippo (2007)”. Can be used as appropriate.
本実施形態の治療剤は、従来薬学的によく知られた形態及び投与経路を適用してヒトなどの対象に投与することができ、例えば、散剤、錠剤、カプセル剤、細粒剤、顆粒剤、シロップ剤、注射剤、眼科用液剤、水性点鼻剤、水性点耳剤、吸入液剤等の製剤として経口的または非経口的に投与することができる。すなわち本実施形態の治療剤は、有効成分を生理学的に許容されうる担体、賦形剤、結合剤、希釈剤などと混合し、例えば以上に例示したような剤形で製造することができる。
The therapeutic agent of the present embodiment can be administered to a subject such as a human by applying conventionally well-known pharmacological forms and administration routes. For example, powders, tablets, capsules, fine granules, granules , Syrups, injections, ophthalmic solutions, aqueous nasal drops, aqueous ear drops, inhalation solutions and the like, and can be administered orally or parenterally. That is, the therapeutic agent of this embodiment can be produced by mixing the active ingredient with a physiologically acceptable carrier, excipient, binder, diluent, etc., for example, in the dosage form as exemplified above.
本実施形態の治療剤においては、副作用の低減、服用容易な小型の製剤化、耐性菌出現の阻止という点で、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量の最小量として、好ましくは１０ｍｇ以上、２０ｍｇ以上、５０ｍｇ以上、１００ｍｇ以上、１２５ｍｇ以上、又は１５０ｍｇ以上が挙げられる。また、１日あたりの投与量の最大量として、好ましくは３００ｍｇ以下、２５０ｍｇ以下、２００ｍｇ以下、又は１７５ｍｇ以下が挙げられる。７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量として、例えば、１０ｍｇ以上３００ｍｇ以下が挙げられ、より好ましくは２０ｍｇ以上２５０ｍｇ以下、さらに好ましくは５０ｍｇ以上２００ｍｇ以下、さらにより好ましくは１００ｍｇ以上２００ｍｇ以下、さらにより好ましくは１２５ｍｇ以上１７５ｍｇ以下、特に好ましくは１５０ｍｇが挙げられる。なお、上記の１日あたりの投与量は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の薬学的に許容される塩を用いる場合は、フリー体に換算した値を用いる。１日分の投与量は、１回で投与しても、２～３回に分けて投与してもよいが、１日１回投与が好ましい。また、効果が不十分な場合は１日あたりの投与量の２倍量を用いてもよい。
In the therapeutic agent of the present embodiment, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl}-in terms of reducing side effects, making a small-sized preparation that is easy to take, and preventing the appearance of resistant bacteria. 4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof The minimum daily dose of salt is preferably 10 mg or more, 20 mg or more, 50 mg or more, 100 mg or more, 125 mg or more, or 150 mg or more. The maximum daily dose is preferably 300 mg or less, 250 mg or less, 200 mg or less, or 175 mg or less. 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo The daily dose of 1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is, for example, from 10 mg to 300 mg, more preferably from 20 mg to 250 mg, still more preferably Is from 50 mg to 200 mg, even more preferably from 100 mg to 200 mg, even more preferably from 125 mg to 175 mg, particularly preferably 150 mg. The dose per day is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2 When a pharmaceutically acceptable salt of (fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is used, the value converted into a free form is used. The daily dose may be administered once or divided into 2 to 3 times, but once daily administration is preferred. If the effect is insufficient, a dose twice the daily dose may be used.
さらに、早急に目的とする血中濃度に到達させるために、負荷投与を行うことが好ましい。負荷投与とは、投与初期において１日投与量の増量や１日投与回数を増やすことにより、早期に目的とする血中濃度に到達させるための投与設計を意味する。投与初期とは投与開始１日目～３日目を意味し、好ましくは投与開始１日目～２日目、さらに好ましくは投与開始１日目を意味する。また、１日投与量の増量として、好ましくは１日あたりの投与量の２倍量を用いる。
Furthermore, it is preferable to perform loading administration in order to quickly reach the target blood concentration. The loading administration means an administration design for reaching a target blood concentration at an early stage by increasing the daily dosage or increasing the number of daily administrations at the initial stage of administration. The initial period of administration means the first day to the third day of the start of administration, preferably the first day to the second day of the start of administration, and more preferably the first day of the start of administration. In addition, as an increase in daily dose, preferably twice the daily dose is used.
負荷投与を行う場合は、投与開始１日目に１日あたりの投与量の２倍量を用いることが好ましい。より好ましい、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量は、フリー体に換算して、投与開始日は３００ｍｇであり、投与２日目以降は１５０ｍｇである。
When carrying out loading administration, it is preferable to use twice the daily dose on the first day of administration. More preferred is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy- The daily dose of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 300 mg on the administration start date in terms of free form, After the first day, it is 150 mg.
７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸塩酸塩の投与量として、好ましくは、投与開始日は３００ｍｇであり、投与２日目以降は１５０ｍｇである。ここで、当該投与量は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸塩酸塩を、フリー体に換算した値を意味する。
7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo The dose of 1,4-dihydroquinoline-3-carboxylic acid hydrochloride is preferably 300 mg on the administration start date and 150 mg on and after the second administration date. Here, the dose is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) It means a value obtained by converting -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride into a free form.
７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の薬学的に許容される塩とは、薬学上許容される塩を使用できる。薬学上許容される塩としては、例えば、塩酸、臭化水素酸、硫酸、リン酸等の無機酸との塩、マレイン酸、フマル酸、コハク酸、リンゴ酸、マロン酸、メタンスルホン酸、トルエンスルホン酸、ベンゼンスルホン酸、乳酸、シュウ酸、酢酸、トリフルオロ酢酸、酒石酸等の有機酸との塩、またはナトリウム、カリウム、マグネシウム、カルシウム、アルミニウム、セシウム、クロム、コバルト、銅、鉄、亜鉛、白金、銀等の金属との塩が挙げられる。このうち、特に好ましくは塩酸塩が挙げられる。
7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo As the pharmaceutically acceptable salt of 1,4-dihydroquinoline-3-carboxylic acid, a pharmaceutically acceptable salt can be used. Examples of the pharmaceutically acceptable salt include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, maleic acid, fumaric acid, succinic acid, malic acid, malonic acid, methanesulfonic acid, toluene. Salts with organic acids such as sulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, acetic acid, trifluoroacetic acid, tartaric acid, or sodium, potassium, magnesium, calcium, aluminum, cesium, chromium, cobalt, copper, iron, zinc, Examples thereof include salts with metals such as platinum and silver. Of these, hydrochloride is particularly preferable. *
なお、「フリー体」とは、塩、共結晶及び水和物のいずれの形態でもない、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸を意味し、分子式はＣ２１Ｈ２４Ｆ３Ｎ３Ｏ４、分子量は４３９．４４の化合物である。
The “free form” means 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidine-1 which is neither a salt, a co-crystal nor a hydrate. -Yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, the molecular formula is C 21 H 24 F 3 N 3 O 4 is a compound having a molecular weight of 439.44.
本実施形態の治療剤は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩が有効成分として単独で構成されるようにしてもよい。または、本実施形態の治療剤は、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩と、有効成分として作用する他の化合物および／または薬学的に許容される添加剤とを含有する医薬組成物として構成されるようにしてもよい。
The therapeutic agent of this embodiment is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof may be constituted alone as an active ingredient. Alternatively, the therapeutic agent of this embodiment is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoro Ethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, other compounds acting as active ingredients and / or pharmaceutically acceptable You may make it comprise as a pharmaceutical composition containing an additive.
当該医薬組成物は、有効成分として作用する他の化合物および／または薬学的に許容される添加剤として、１種または複数の化合物を含有することができる。当該医薬組成物は、例えば、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩と、有効成分として作用する他の化合物および添加剤のうち１種以上とを混和することにより調製される。
The pharmaceutical composition may contain one or more compounds as other compounds that act as active ingredients and / or pharmaceutically acceptable additives. The pharmaceutical composition is, for example, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof and one or more other compounds and additives that act as active ingredients To be prepared.
以上、本実施形態によれば、誤嚥性肺炎、肺化膿症又は肺膿瘍に対して、高い治療効果と安全性を有する治療剤に関する技術を提供することができる。本件明細書に記載の適切な組成物を用いることで、少ない投与量を用いた場合でも、副作用を低減し、耐性菌の出現頻度を減弱しながらも、十分な治療効果を得ることができる。
（実施例） As mentioned above, according to this embodiment, the technique regarding the therapeutic agent which has a high therapeutic effect and safety | security with respect to aspiration pneumonia, pulmonary abscess, or a lung abscess can be provided. By using an appropriate composition described in the present specification, even when a small dose is used, a sufficient therapeutic effect can be obtained while reducing side effects and reducing the appearance frequency of resistant bacteria.
(Example)
（実施例） As mentioned above, according to this embodiment, the technique regarding the therapeutic agent which has a high therapeutic effect and safety | security with respect to aspiration pneumonia, pulmonary abscess, or a lung abscess can be provided. By using an appropriate composition described in the present specification, even when a small dose is used, a sufficient therapeutic effect can be obtained while reducing side effects and reducing the appearance frequency of resistant bacteria.
(Example)
以下に実施例を示して本発明を更に詳細に説明するが、これら実施例によって本発明の範囲が限定されるものではない。
国際公開第２０１６／１９５０１４号に開示されている方法に準じて、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の１５０ｍｇ注射剤（以下、治験薬Ａとも記載する）を製造した。 The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited by these examples.
According to the method disclosed in WO2016 / 195014, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro A 150 mg injection of -1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (hereinafter also referred to as study drug A) was prepared.
国際公開第２０１６／１９５０１４号に開示されている方法に準じて、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸の１５０ｍｇ注射剤（以下、治験薬Ａとも記載する）を製造した。 The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited by these examples.
According to the method disclosed in WO2016 / 195014, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro A 150 mg injection of -1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (hereinafter also referred to as study drug A) was prepared.
なお、１５０ｍｇ注射剤の「１５０ｍｇ」とは７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸塩酸塩をフリー体換算した場合の重量を示している。注射剤の製造の際には ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸塩酸塩１６２．５ｍｇ（フリー体換算：１５０ｍｇ）を使用している。
（試験例１）誤嚥性肺炎
治験薬Ａを、下記の基準を満たす誤嚥性肺炎を疑われる被験者１３例に対し、７日間～１４日間点滴静脈内投与した。
・１６歳以上で投与開始前４８時間以内に撮影された胸部Ｘ線またはＣＴ画像上に急性に出現した明らかな浸潤影を認める。
・明らかな誤嚥が確認、むせや嚥下機能障害、嚥下機能障害の可能性をもつ疾患を有しているまたは既往歴を有する。
・誤嚥性肺炎に特徴的な症状、炎症所見を示す。
投与開始１日目は治験薬Ａを２本（３００ｍｇ／日）、投与２日目は治験薬Ａを１本（１５０ｍｇ／日）用い、その後同投与量（１５０ｍｇ／日）を維持した。注射剤の投与は１本あたり約１時間かけて点滴静脈内投与を行った。
（試験例２）肺化膿症又は肺膿瘍
治験薬Ａを、下記の基準を満たす肺化膿症又は肺膿瘍を疑われる披験者１１例に対し、７日間～１４日間点滴静脈内投与した。
・１６歳以上で、投与開始前４８時間以内に撮影された胸部Ｘ線またはＣＴ画像上、塊状影または内部に空洞を伴う陰影（結節影、腫瘤影）を認める。なお、膿の貯留による鏡面像の有無は問わない。
・肺化膿症・肺膿瘍に特徴的な症状、炎症所見を示す。
投与開始１日目は治験薬Ａを２本（３００ｍｇ／日）、投与２日目は治験薬Ａを１本（１５０ｍｇ／日）用い、その後同投与量（１５０ｍｇ／日）を維持した。注射剤の投与は１本あたり約１時間かけて点滴静脈内投与を行った。
試験例１、２の臨床効果は、呼吸器感染症における新規抗菌薬の臨床評価法(第二版)、日化療会誌. 2012; 60(1): 30-45. 9 )の肺炎の臨床効果判定基準を基に、下記の基準を設定し、判定を行なった。なお、主要評価項目は、治験薬Ａの投与終了時又は中止時の有効率とした。 Note that “150 mg” of 150 mg injection is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2- It shows the weight when fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride is converted to free form. When producing an injection, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) Use is made of 162.5 mg (converted to free form: 150 mg) of -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.
(Test Example 1) Aspiration pneumonia Study drug A was administered intravenously for 7 to 14 days to 13 subjects suspected of having aspiration pneumonia meeting the following criteria.
・ A clear infiltration shadow appears acutely on chest X-rays or CT images taken within 48 hours before the start of administration at the age of 16 years or older.
・ Confirmation of clear aspiration, disease or dysphagia, potential dysphagia, or history.
-Symptoms and inflammation that are characteristic of aspiration pneumonia.
On the first day of administration, two investigational drugs A (300 mg / day) were used, and on the second day of administration, one investigational drug A (150 mg / day) was used, and then the same dose (150 mg / day) was maintained. The injection was administered by intravenous infusion over about 1 hour per one.
(Test Example 2) Pulmonary abscess or lung abscess investigational drug A was intravenously administered intravenously for 7 to 14 days to 11 subjects suspected of having pulmonary abscess or lung abscess satisfying the following criteria.
-Chest X-rays or CT images taken within 48 hours prior to the start of administration at the age of 16 years or older, a massive shadow or a shadow with a cavity (nodular shadow, tumor shadow) is observed. In addition, the presence or absence of the specular image by the accumulation of pus does not ask | require.
-Symptoms and inflammation that are characteristic of pulmonary abscess and lung abscess.
On the first day of administration, two investigational drugs A (300 mg / day) were used, and on the second day of administration, one investigational drug A (150 mg / day) was used, and then the same dose (150 mg / day) was maintained. The injection was administered by intravenous infusion over about 1 hour per one.
The clinical effects of Test Examples 1 and 2 are as follows: Clinical evaluation of new antibacterial agents in respiratory infections (2nd edition), JCIA Journal. 2012; 60 (1): 30-45. 9) Based on the judgment criteria, the following criteria were set and judged. The primary endpoint was the effective rate at the end of administration or discontinuation of study drug A.
（試験例１）誤嚥性肺炎
治験薬Ａを、下記の基準を満たす誤嚥性肺炎を疑われる被験者１３例に対し、７日間～１４日間点滴静脈内投与した。
・１６歳以上で投与開始前４８時間以内に撮影された胸部Ｘ線またはＣＴ画像上に急性に出現した明らかな浸潤影を認める。
・明らかな誤嚥が確認、むせや嚥下機能障害、嚥下機能障害の可能性をもつ疾患を有しているまたは既往歴を有する。
・誤嚥性肺炎に特徴的な症状、炎症所見を示す。
投与開始１日目は治験薬Ａを２本（３００ｍｇ／日）、投与２日目は治験薬Ａを１本（１５０ｍｇ／日）用い、その後同投与量（１５０ｍｇ／日）を維持した。注射剤の投与は１本あたり約１時間かけて点滴静脈内投与を行った。
（試験例２）肺化膿症又は肺膿瘍
治験薬Ａを、下記の基準を満たす肺化膿症又は肺膿瘍を疑われる披験者１１例に対し、７日間～１４日間点滴静脈内投与した。
・１６歳以上で、投与開始前４８時間以内に撮影された胸部Ｘ線またはＣＴ画像上、塊状影または内部に空洞を伴う陰影（結節影、腫瘤影）を認める。なお、膿の貯留による鏡面像の有無は問わない。
・肺化膿症・肺膿瘍に特徴的な症状、炎症所見を示す。
投与開始１日目は治験薬Ａを２本（３００ｍｇ／日）、投与２日目は治験薬Ａを１本（１５０ｍｇ／日）用い、その後同投与量（１５０ｍｇ／日）を維持した。注射剤の投与は１本あたり約１時間かけて点滴静脈内投与を行った。
試験例１、２の臨床効果は、呼吸器感染症における新規抗菌薬の臨床評価法(第二版)、日化療会誌. 2012; 60(1): 30-45. 9 )の肺炎の臨床効果判定基準を基に、下記の基準を設定し、判定を行なった。なお、主要評価項目は、治験薬Ａの投与終了時又は中止時の有効率とした。 Note that “150 mg” of 150 mg injection is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2- It shows the weight when fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride is converted to free form. When producing an injection, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) Use is made of 162.5 mg (converted to free form: 150 mg) of -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride.
(Test Example 1) Aspiration pneumonia Study drug A was administered intravenously for 7 to 14 days to 13 subjects suspected of having aspiration pneumonia meeting the following criteria.
・ A clear infiltration shadow appears acutely on chest X-rays or CT images taken within 48 hours before the start of administration at the age of 16 years or older.
・ Confirmation of clear aspiration, disease or dysphagia, potential dysphagia, or history.
-Symptoms and inflammation that are characteristic of aspiration pneumonia.
On the first day of administration, two investigational drugs A (300 mg / day) were used, and on the second day of administration, one investigational drug A (150 mg / day) was used, and then the same dose (150 mg / day) was maintained. The injection was administered by intravenous infusion over about 1 hour per one.
(Test Example 2) Pulmonary abscess or lung abscess investigational drug A was intravenously administered intravenously for 7 to 14 days to 11 subjects suspected of having pulmonary abscess or lung abscess satisfying the following criteria.
-Chest X-rays or CT images taken within 48 hours prior to the start of administration at the age of 16 years or older, a massive shadow or a shadow with a cavity (nodular shadow, tumor shadow) is observed. In addition, the presence or absence of the specular image by the accumulation of pus does not ask | require.
-Symptoms and inflammation that are characteristic of pulmonary abscess and lung abscess.
On the first day of administration, two investigational drugs A (300 mg / day) were used, and on the second day of administration, one investigational drug A (150 mg / day) was used, and then the same dose (150 mg / day) was maintained. The injection was administered by intravenous infusion over about 1 hour per one.
The clinical effects of Test Examples 1 and 2 are as follows: Clinical evaluation of new antibacterial agents in respiratory infections (2nd edition), JCIA Journal. 2012; 60 (1): 30-45. 9) Based on the judgment criteria, the following criteria were set and judged. The primary endpoint was the effective rate at the end of administration or discontinuation of study drug A.
本明細書において、投与終了時とは、治験薬Ａの投与が完了した日の翌日の評価日を意味する。また、中止時とは、治験薬Ａの最終投与日又は中止判断日から３日以内に実施した評価日を意味する。さらに、「投与終了時又は中止時」を治療終了時（EOT、End of Treatment)と表現する。また、CRPとは、C-reactive proteinの略称であり、各種炎症に反応して短時間に産生される急性相反応物質のひとつである。肺炎などの細菌感染症では数時間で上昇し、炎症の沈静化に伴い速やかに減少するので、治療効果の観察に役立つ指標である。
・早期薬効評価及び治療終了時(EOT)
早期薬効評価は、投与3日後に表１に従い、「早期治療効果あり」「早期治療効果なし」「判定不能」の3段階で判定した。
「早期治療効果あり」の定義は、投与3日後に著しい改善を認めた症例(4日後以降の投与終了・継続とは無関係)とした。また、投与開始前に比べて、投与3日後のCRP値や胸部X線が改善していない症例については、CRPや胸部X線所見が不変又は悪化にもかかわらず、臨床症状及び体温の改善がある場合は「早期治療効果あり」と判断した。
CRPや胸部X線所見が不変又は悪化し、臨床症状及び体温が不変又は改善がない場合は、「早期治療効果なし」と判定し、被験者の安全を十分に考慮し、治験を中止し他の抗菌薬投与に切り替えるなど治験責任医師等が適切に判断した。なお、適切な代替の抗菌薬治療を開始する前に、微生物学的評価のための検体を採取した。 In the present specification, the term “at the end of administration” means the evaluation date on the day after the administration of the investigational drug A is completed. Moreover, the time of discontinuation means the evaluation date implemented within 3 days from the last administration date or the discontinuation judgment date of the investigational drug A. Furthermore, “when administration is completed or stopped” is expressed as treatment end (EOT, End of Treatment). CRP is an abbreviation for C-reactive protein, and is one of the acute phase reactants produced in a short time in response to various inflammations. Bacterial infections such as pneumonia increase in a few hours and decrease rapidly as the inflammation subsides. This is a useful index for observation of therapeutic effects.
・ Early efficacy evaluation and end of treatment (EOT)
The early drug efficacy evaluation was determined according to Table 1, 3 days after administration, in three stages: “Early therapeutic effect”, “No early therapeutic effect”, and “Undeterminable”.
The definition of “with early treatment effect” was defined as a case in which significant improvement was observed 3 days after administration (regardless of whether administration was completed or continued after 4 days). In addition, in cases where CRP values and chest X-rays did not improve 3 days after administration compared to before the start of administration, clinical symptoms and body temperature were improved, although CRP and chest X-ray findings were unchanged or worsened. In some cases, it was judged as “early therapeutic effect”.
If CRP or chest X-ray findings do not change or worsen, and clinical symptoms and body temperature do not change or improve, it is determined that there is no early treatment effect. The investigator made an appropriate decision, such as switching to antibiotics. Samples for microbiological evaluation were collected before starting appropriate alternative antimicrobial treatment.
・早期薬効評価及び治療終了時(EOT)
早期薬効評価は、投与3日後に表１に従い、「早期治療効果あり」「早期治療効果なし」「判定不能」の3段階で判定した。
「早期治療効果あり」の定義は、投与3日後に著しい改善を認めた症例(4日後以降の投与終了・継続とは無関係)とした。また、投与開始前に比べて、投与3日後のCRP値や胸部X線が改善していない症例については、CRPや胸部X線所見が不変又は悪化にもかかわらず、臨床症状及び体温の改善がある場合は「早期治療効果あり」と判断した。
CRPや胸部X線所見が不変又は悪化し、臨床症状及び体温が不変又は改善がない場合は、「早期治療効果なし」と判定し、被験者の安全を十分に考慮し、治験を中止し他の抗菌薬投与に切り替えるなど治験責任医師等が適切に判断した。なお、適切な代替の抗菌薬治療を開始する前に、微生物学的評価のための検体を採取した。 In the present specification, the term “at the end of administration” means the evaluation date on the day after the administration of the investigational drug A is completed. Moreover, the time of discontinuation means the evaluation date implemented within 3 days from the last administration date or the discontinuation judgment date of the investigational drug A. Furthermore, “when administration is completed or stopped” is expressed as treatment end (EOT, End of Treatment). CRP is an abbreviation for C-reactive protein, and is one of the acute phase reactants produced in a short time in response to various inflammations. Bacterial infections such as pneumonia increase in a few hours and decrease rapidly as the inflammation subsides. This is a useful index for observation of therapeutic effects.
・ Early efficacy evaluation and end of treatment (EOT)
The early drug efficacy evaluation was determined according to Table 1, 3 days after administration, in three stages: “Early therapeutic effect”, “No early therapeutic effect”, and “Undeterminable”.
The definition of “with early treatment effect” was defined as a case in which significant improvement was observed 3 days after administration (regardless of whether administration was completed or continued after 4 days). In addition, in cases where CRP values and chest X-rays did not improve 3 days after administration compared to before the start of administration, clinical symptoms and body temperature were improved, although CRP and chest X-ray findings were unchanged or worsened. In some cases, it was judged as “early therapeutic effect”.
If CRP or chest X-ray findings do not change or worsen, and clinical symptoms and body temperature do not change or improve, it is determined that there is no early treatment effect. The investigator made an appropriate decision, such as switching to antibiotics. Samples for microbiological evaluation were collected before starting appropriate alternative antimicrobial treatment.
また、中止日が投与開始日(0日)又は投与2日目(1日)の場合、早期薬効評価の判定は不要とした。投与3日目(2日)以降の場合は、中止時の検査結果を用いて判定した。
治療終了時(EOT)は、投与終了時又は中止時の臨床効果について、表１に従い、「有効」「無効」「判定不能」の３段階で判定した。投与終了時翌日以降に中止した場合は、投与終了時の臨床効果について判定し、中止時の臨床効果は判定不要とした。
また、中止した場合又は治験薬投与終了後に代替の抗菌薬治療に変更した場合は「無効」と判断した。ただし、治療終了時(EOT)に表１の判定基準に従い「有効」と判断された場合は、代替の抗菌薬治療に変更した場合であっても、この限りではない。なお、代替の抗菌薬治療に変更する場合は、原則変更前に規定の検査、診察及び治療終了時の判定を実施した。 In addition, when the discontinuation date is the start date of administration (day 0) or the second day of administration (day 1), the determination of early drug efficacy is unnecessary. In the case of the 3rd day after administration (2nd day) or later, the test result at the time of discontinuation was used.
At the end of treatment (EOT), the clinical effects at the end of administration or at the time of discontinuation were determined according to Table 1 in three stages: “effective”, “invalid”, and “undecidable”. When the treatment was discontinued after the next day after the end of the administration, the clinical effect at the end of the administration was determined, and the clinical effect at the time of the discontinuation was unnecessary.
In addition, it was judged as “invalid” when it was discontinued or when it was changed to an alternative antibacterial treatment after the end of study drug administration. However, this does not apply to cases where it is determined to be “effective” at the end of treatment (EOT) in accordance with the criteria shown in Table 1, even if it is changed to alternative antimicrobial treatment. In addition, when changing to an alternative antibacterial treatment, prescribed tests, examinations and judgments at the end of treatment were conducted before the principle change.
治療終了時(EOT)は、投与終了時又は中止時の臨床効果について、表１に従い、「有効」「無効」「判定不能」の３段階で判定した。投与終了時翌日以降に中止した場合は、投与終了時の臨床効果について判定し、中止時の臨床効果は判定不要とした。
また、中止した場合又は治験薬投与終了後に代替の抗菌薬治療に変更した場合は「無効」と判断した。ただし、治療終了時(EOT)に表１の判定基準に従い「有効」と判断された場合は、代替の抗菌薬治療に変更した場合であっても、この限りではない。なお、代替の抗菌薬治療に変更する場合は、原則変更前に規定の検査、診察及び治療終了時の判定を実施した。 In addition, when the discontinuation date is the start date of administration (day 0) or the second day of administration (day 1), the determination of early drug efficacy is unnecessary. In the case of the 3rd day after administration (2nd day) or later, the test result at the time of discontinuation was used.
At the end of treatment (EOT), the clinical effects at the end of administration or at the time of discontinuation were determined according to Table 1 in three stages: “effective”, “invalid”, and “undecidable”. When the treatment was discontinued after the next day after the end of the administration, the clinical effect at the end of the administration was determined, and the clinical effect at the time of the discontinuation was unnecessary.
In addition, it was judged as “invalid” when it was discontinued or when it was changed to an alternative antibacterial treatment after the end of study drug administration. However, this does not apply to cases where it is determined to be “effective” at the end of treatment (EOT) in accordance with the criteria shown in Table 1, even if it is changed to alternative antimicrobial treatment. In addition, when changing to an alternative antibacterial treatment, prescribed tests, examinations and judgments at the end of treatment were conducted before the principle change.
試験例１及び２の、早期薬効評価及び治療終了時の結果を表２及び表３に示す。
Tables 2 and 3 show the results of early drug efficacy evaluation and treatment completion in Test Examples 1 and 2.
なお、有効率とは以下の式で求めた値である。
有効率＝（「有効」と判定された被験者数÷「有効」又は「無効」と判定された被験者数）×１００ （％） The effective rate is a value obtained by the following formula.
Effective rate = (number of subjects judged “valid” ÷ number of subjects judged “valid” or “invalid”) × 100 (%)
有効率＝（「有効」と判定された被験者数÷「有効」又は「無効」と判定された被験者数）×１００ （％） The effective rate is a value obtained by the following formula.
Effective rate = (number of subjects judged “valid” ÷ number of subjects judged “valid” or “invalid”) × 100 (%)
表２及び表３から、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸がまたは薬学的に許容されるその塩が誤嚥性肺炎、肺化膿症又は肺膿瘍に対し、高い治療効果を発揮することが分かる。特に治療終了時の有効率は、誤嚥性肺炎については１００％、肺化膿症又は肺膿瘍に対しては９１％と著しく高い。
From Table 2 and Table 3, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl)- 8-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof has a high therapeutic effect on aspiration pneumonia, pulmonary abscess or lung abscess I understand that. In particular, the effective rate at the end of treatment is as high as 100% for aspiration pneumonia and 91% for pulmonary abscess or lung abscess.
試験例１及び２の、起因菌別の微生物学的効果を表４及び表５に示す。
Tables 4 and 5 show the microbiological effects of Test Examples 1 and 2 according to the causative bacteria.
表４及び表５から、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸がまたは薬学的に許容されるその塩が誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌に対し、高い抗菌効果を発揮することが分かる。
From Table 4 and Table 5, 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl)- 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof has a high antibacterial effect on the pathogenic bacteria of aspiration pneumonia, pulmonary abscess or lung abscess It can be seen that
本実施形態によれば、誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤を提供することが可能であり、産業上有用である。
According to this embodiment, it is possible to provide a therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess, which is industrially useful.
Claims (12)
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo A therapeutic agent for aspiration pneumonia, pulmonary abscess or lung abscess containing 1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する誤嚥性肺炎の治療剤。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo A therapeutic agent for aspiration pneumonia containing 1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩を有効成分として含有する肺化膿症又は肺膿瘍の治療剤。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo A therapeutic agent for pulmonary abscess or lung abscess comprising 1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
- 前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、請求項１に記載の治療剤。 Aspiration pneumonia, pulmonary abscess or lung abscess causing bacteria belonging to the genus Prebotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphyrus, bacteria belonging to the genus Finegordia The therapeutic agent according to claim 1, which is one or more bacteria selected from the group consisting of bacteria belonging to the genus Fusobacterium.
- 前記誤嚥性肺炎の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、請求項２に記載の治療剤。 Bacteria belonging to the genus Prevotella, bacteria belonging to the genus Peptostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Peptoniphylla, bacteria belonging to the genus Finegordia, and bacteria belonging to the genus Fusobacterium The therapeutic agent according to claim 2, which is one or more bacteria selected from the group consisting of.
- 前記肺化膿症又は肺膿瘍の起因菌が、プレボテラ属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ペプトニフィラス属に属する菌、ファインゴルディア属に属する菌及び、フソバクテリウム属に属する菌、からなる群から選ばれる１種または２種以上の菌である、請求項３に記載の治療剤。 The pulmonary abscess or pulmonary abscess-causing bacterium is a bacterium belonging to the genus Prebotella, a bacterium belonging to the genus Peptostreptococcus, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Peptoniphyrus, a bacterium belonging to the genus Finegordia, and a genus Fusobacterium. The therapeutic agent of Claim 3 which is 1 type, or 2 or more types of microbe chosen from the group which consists of a microbe to which it belongs.
- 前記誤嚥性肺炎、肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、ストレプトコッカス・アンギノーサスグループ、及びアクチノマイセス属に属する菌からなる群から選ばれる１種または２種以上の菌である、請求項１に記載の治療剤。 Bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Prevotella, bacteria belonging to the genus Porphyromonas, bacteria belonging to the genus Fusobacterium, bacteria belonging to the genus Leptotricia, pep One or two species selected from the group consisting of bacteria belonging to the genus Tostreptococcus, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Bayonella, bacteria belonging to the genus Tissierella, Streptococcus anginosas group, and bacteria belonging to the genus Actinomyces The therapeutic agent of Claim 1 which is the above microbe.
- 前記誤嚥性肺炎の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌及びアクチノマイセス属からなる群から選ばれる１種または２種以上の菌である、請求項２に記載の治療剤。 One or more kinds selected from the group consisting of bacteria belonging to the genus Bacteroides, bacteria belonging to the genus Prevoterra, bacteria belonging to the genus Parvimonas, bacteria belonging to the genus Bayonella and the genus Actinomyces The therapeutic agent according to claim 2, wherein
- 前記肺化膿症又は肺膿瘍の起因菌が、バクテロイデス属に属する菌、プレボテラ属に属する菌、ポルフィロモナス属に属する菌、フソバクテリウム属に属する菌、レプトトリキア属に属する菌、ペプトストレプトコッカス属に属する菌、パルビモナス属に属する菌、ベイヨネラ属に属する菌、ティシエレラ属に属する菌、及びストレプトコッカス・アンギノーサスグループからなる群から選ばれる１種または２種以上の菌である、請求項３に記載の治療剤。 The pulmonary abscess or pulmonary abscess-causing bacterium belongs to the genus Bacteroides, the bacterium belonging to the genus Prevotella, the bacterium belonging to the genus Porphyromonas, the bacterium belonging to the genus Fusobacterium, the bacterium belonging to the genus Leptotricia, or the genus Peptostreptococcus The treatment according to claim 3, which is one or more bacteria selected from the group consisting of a bacterium, a bacterium belonging to the genus Parvimonas, a bacterium belonging to the genus Bayonella, a bacterium belonging to the genus Tisierella, and a Streptococcus anginosus group. Agent.
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、請求項１に記載の治療剤。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo The daily dose of -1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl}- 4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid in terms of start date of administration Is 300 mg, and the therapeutic agent according to claim 1, which is 150 mg after the second day of administration.
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、請求項２に記載の治療剤。 7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo The daily dose of -1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl}- 4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid in terms of start date of administration Is 300 mg, and the therapeutic agent according to claim 2, which is 150 mg after the second day of administration.
- ７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸または薬学的に許容されるその塩の１日あたりの投与量が、７－［（３Ｓ，４Ｓ）－３－｛（シクロプロピルアミノ）メチル｝－４－フルオロピロリジン－１－イル］－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１，４－ジヒドロキノリン－３－カルボン酸に換算して、投与開始日が３００ｍｇであり、投与２日目以降は１５０ｍｇである、請求項３に記載の治療剤。
7-[(3S, 4S) -3-{(cyclopropylamino) methyl} -4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo The daily dose of -1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is 7-[(3S, 4S) -3-{(cyclopropylamino) methyl}- 4-fluoropyrrolidin-1-yl] -6-fluoro-1- (2-fluoroethyl) -8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid in terms of start date of administration Is 300 mg, and the therapeutic agent according to claim 3, which is 150 mg after the second day of administration.
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA202090066A EA202090066A1 (en) | 2018-03-30 | 2018-06-15 | THERAPEUTIC FOR THE TREATMENT OF ASPIRATED PNEUMONIA, PULMONARY FORCING OR LUNG ABCESS |
| AU2018283234A AU2018283234A1 (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| JP2019525551A JP6618660B2 (en) | 2017-06-16 | 2018-06-15 | Treatment for aspiration pneumonia, pulmonary abscess or lung abscess |
| US16/620,630 US20210137913A1 (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| MX2019014931A MX2019014931A (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess. |
| CN202310755318.XA CN116549446A (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration or lung abscess |
| SG11201911826VA SG11201911826VA (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| KR1020207000644A KR20200016960A (en) | 2017-06-16 | 2018-06-15 | Drugs for aspiration pneumonia, pneumonia, or lung abscess |
| CN201880039674.9A CN110891571A (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration or lung abscess |
| CA3067188A CA3067188A1 (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| BR112019025960-0A BR112019025960A2 (en) | 2017-06-16 | 2018-06-15 | therapeutic agent for aspiration pneumonia, lung suppuration or lung abscess |
| EP18818391.7A EP3639826A4 (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| IL270831A IL270831A (en) | 2017-06-16 | 2019-11-21 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| PH12019502835A PH12019502835A1 (en) | 2017-06-16 | 2019-12-16 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520961P | 2017-06-16 | 2017-06-16 | |
| US62/520,961 | 2017-06-16 | ||
| JP2018-068159 | 2018-03-30 | ||
| JP2018068159 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018230686A1 true WO2018230686A1 (en) | 2018-12-20 |
Family
ID=64660738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2018/022846 WO2018230686A1 (en) | 2017-06-16 | 2018-06-15 | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN116549446A (en) |
| EA (1) | EA202090066A1 (en) |
| WO (1) | WO2018230686A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005026147A1 (en) | 2003-09-10 | 2005-03-24 | Kyorin Pharmaceutical Co., Ltd. | 7-(4-substituted 3- cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative |
| WO2013069297A1 (en) | 2011-11-10 | 2013-05-16 | 杏林製薬株式会社 | 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal |
| WO2016148066A1 (en) * | 2015-03-13 | 2016-09-22 | 杏林製薬株式会社 | Respiratory infection treating agent |
| WO2016195014A1 (en) | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | Aqueous drug |
-
2018
- 2018-06-15 WO PCT/JP2018/022846 patent/WO2018230686A1/en active Application Filing
- 2018-06-15 CN CN202310755318.XA patent/CN116549446A/en active Pending
- 2018-06-15 EA EA202090066A patent/EA202090066A1/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005026147A1 (en) | 2003-09-10 | 2005-03-24 | Kyorin Pharmaceutical Co., Ltd. | 7-(4-substituted 3- cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative |
| WO2013069297A1 (en) | 2011-11-10 | 2013-05-16 | 杏林製薬株式会社 | 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal |
| WO2016148066A1 (en) * | 2015-03-13 | 2016-09-22 | 杏林製薬株式会社 | Respiratory infection treating agent |
| WO2016195014A1 (en) | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | Aqueous drug |
Non-Patent Citations (12)
| Title |
|---|
| "Japanese Journal of Chemotherapy", vol. 60, 2012, article "Clinical evaluation method of new antibacterial drugs in respiratory infections", pages: 30 - 45 |
| "Pharmaceutical Additives Dictionary", 2007, YAKUJI NIPPO, article "International Pharmaceutical Excipients Council Japan" |
| ALLEWELT, M. ET AL.: "Ampicillin + sulbactam vs. clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess", CLIN. MICROBIOL. INFECT., vol. 10, 2004, pages 163 - 170, XP055565382, ISSN: 1198-743X * |
| ANNALS OF THE JAPANESE RESPIRATORY SOCIETY, vol. 49, no. 9, 2011, pages 623 - 628 |
| BARTLETT, JOHN G. ET AL.: "The Bacteriology of Aspiration Pneumonia", THE AMERICAN JOURNAL OF MEDICINE, vol. 56, 1974, pages 202 - 207, XP023215014, ISSN: 0002-9343 * |
| EL-SOLH, ALI A. ET AL.: "Microbiology of Severe Aspiration Pneumonia in Institutionalized Elderly", AM. J. RESPIR. CRIT. CARE. MED., vol. 167, 2003, pages 1650 - 1654, XP055565392, ISSN: 1073-449X * |
| EXPERT REVIEW OF RESPIRATORY MEDICINE, vol. 1, no. 1, 2007, pages 111 - 119 |
| INFECTION (MUNICH, GERMANY, vol. 36, no. 1, 2008, pages 23 - 30 |
| NIPPON KAGAKU RYOHO GAKKAI ZASSHI, vol. 47, no. 1, 1999, pages 196 - 203 |
| THE JAPANESE RESPIRATORY SOCIETY, ADULT PNEUMONIA CLINICAL PRACTICE GUIDELINES, 2017, pages 24 |
| THE JAPANESE RESPIRATORY SOCIETY, MEDICAL/CARE-RELATED PNEUMONIA CLINICAL PRACTICE GUIDELINES, pages 23 |
| THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 99, no. 11, 10 November 2010 (2010-11-10), pages 2746 - 2751 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116549446A (en) | 2023-08-08 |
| EA202090066A1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10792289B2 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| JP6618660B2 (en) | Treatment for aspiration pneumonia, pulmonary abscess or lung abscess | |
| WO2022042546A1 (en) | Combined antibacterial pharmaceutical composition and use thereof | |
| WO2018230686A1 (en) | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess | |
| JP6077725B1 (en) | Respiratory infection treatment | |
| US20030073625A1 (en) | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides | |
| AU2015275224C1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| JP2017137289A5 (en) | ||
| JP2017137289A (en) | Fluoroquinolone formulations for cystic fibrosis | |
| Varma et al. | Anaesthesia for thymectomy: Use of ketamine-dexmedetomidine without muscle relaxant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18818391 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2019525551 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2018283234 Country of ref document: AU Date of ref document: 20180615 Kind code of ref document: A Ref document number: 3067188 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019025960 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 20207000644 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2018818391 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2018818391 Country of ref document: EP Effective date: 20200116 |
|
| ENP | Entry into the national phase |
Ref document number: 112019025960 Country of ref document: BR Kind code of ref document: A2 Effective date: 20191208 |